A study on biochemical parameters ECR,CRP, uric acid and fibrinogen for prediction of functional outcome in patients with ischemic stroke  at government Stanley hospital Chennai – 600 001. by Vinod Kumar, R
                                           DISSERTATION  
 
A STUDY ON BIOCHEMICAL PARAMETERS ESR,CRP, URIC    
ACID AND FIBRINOGEN FOR PREDICTION OF FUNCTIONAL 
OUTCOME IN PATIENTS WITH ISCHEMIC STROKE AT    
GOVERNMENT STANLEY HOSPITAL CHENNAI – 600 001. 
 
Dissertation Submitted to 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI  –  600032. 
 
In partial fulfillment of the Regulations 
for the Award of the Degree of 
 
                 M.D. BRANCH - I 
GENERAL MEDICINE 
APRIL 2015 
 
  
 
 
 
 
 
 
 
DEPARTMENT OF GENERAL MEDICINE 
GOVT. STANLEY MEDICAL COLLEGE & HOSPITAL 
CHENNAI - TAMILNADU 
 
 
CERTIFICATE BY INSTITUTION 
 
 
 
This is to certify that Dr. VINOD KUMAR. R, Post - Graduate Student (MAY 
2012 TO APRIL 2015) in the Department of General Medicine STANLEY 
MEDICAL COLLEGE, Chennai- 600 001, has done this dissertation on “A 
STUDY ON BIOCHEMICAL PARAMETERS ESR,CRP, URIC    
ACID AND FIBRINOGEN FOR PREDICTION OF FUNCTIONAL 
OUTCOME IN PATIENTS WITH ISCHEMIC STROKE AT    
GOVERNMENT STANLEY HOSPITAL CHENNAI – 600 001”.   
under my guidance and supervision in partial fulfillment of the regulations 
laiddown by the TamilnaduDr.M.G.R. Medical University, Chennai, for M.D.  
(General Medicine), Degree Examination to be held in April 2015. 
 
 
Dr.R.JAYANTHI M.D.        Dr.AL.MEENAKSHI SUNDARAM M.D.,D.A. 
Professor & HOD                                                                         Dean 
Department of Medicine                                             Govt. Stanley medical College & Hospital 
Govt. Stanley Medical College & Hospital                   Chennai 600001 
Chennai 600001 
 
 
 
 
 
 
CERTIFICATE BY GUIDE 
 
 
This is to certify that Dr. VINOD KUMAR.R Post - Graduate Student (MAY 
2012 TO APRIL 2015) in the Department of General Medicine STANLEY 
MEDICAL COLLEGE, Chennai- 600 001, has done this dissertation on “A 
STUDY ON BIOCHEMICAL PARAMETERS ESR,CRP, URIC    
ACID AND FIBRINOGEN FOR PREDICTION OF FUNCTIONAL 
OUTCOME IN PATIENTS WITH ISCHEMIC STROKE AT    
GOVERNMENT STANLEY HOSPITAL CHENNAI – 600 001” under 
my guidance and supervision in partial fulfillment of the regulations laid down 
by the TamilnaduDr.M.G.R. Medical University, Chennai, for M.D.  
(General Medicine), Degree Examination to be held in April 2015. 
 
 
Dr G.VASUMATHI M.D. 
Professor 
Department of Medicine 
Govt. Stanley Medical College & Hospital 
Chennai 600001 
 
 
 
DECLARATION 
I  Dr. VINOD KUMAR. R solemnly declare that I carried out  this  work  
on “A STUDY ON BIOCHEMICAL PARAMETERS ESR,CRP, 
URIC ACID AND FIBRINOGEN FOR PREDICTION OF 
FUNCTIONAL OUTCOME IN PATIENTS WITH ISCHEMIC 
STROKE AT GOVERNMENT STANLEY HOSPITAL 
CHENNAI – 600 001” in the Medical OPD, Medical wards and IMCU 
of Government Stanley Hospital during the period  January 2014 to September 
2014. I also declare that, this bonafide work or a part of this was not submitted 
by me or any other for any award, degree, or diploma to any other university, 
board either in India or abroad. 
This is submitted to The Tamilnadu Dr.M.G.R. Medical University, 
Chennai in partial fulfilment of the rules and regulation for the M.D. Branch I, 
General Medicine Degree examination 
 
DR.VINOD KUMAR. R 
 
 
 
 
 
ACKNOWLEDGEMENT 
My sincere thanks to our Dean Dr.AL.MEENAKSHI SUNDARAM 
M.D.,D.A for permitting me to carry out this study in our hospital. 
I express my profound thanks to my Professor and Teacher 
Dr.R.JAYANTHI, M.D., Professor and HOD of Medicine, Stanley Medical 
College Hospital, for encouraging and extending invaluable guidance to 
perform and complete this dissertation. 
I am immensely thankful to my Teacher Dr.P.VIJAYARAGAVAN, 
M.D., Professor and Former HOD of Medicine, Stanley Medical College 
Hospital, for his guidance & suggestions to perform and complete my 
dissertation 
I am extremely grateful to my  unit chief  Dr.G.VASUMATHI, M.D., Professor  
Of  Medicine who has been the main pillar for this study with her constant 
encouragement  and valuable guidance throughout the study. 
I wish to thank Dr.A.RAMALINGAM, M.D.,and DR.S.M.SUJATHA, M.D.,  
Assistant Professors of my unit, Department of Medicine, Stanley medical 
college Hospital for their valuable suggestions, encouragement and advice. 
I sincerely thank the members of Institutional Ethical Committee, Stanley 
Medical College for approving my dissertation topic. 
I am extremely thankful to DR. ARUN MURUGAN MD., 
DIH, PGHFWM. Assistant Professor of Community Medicine Kilpauk 
Medical College who timely helped me with the statistical work. 
I thank all my Colleagues, House Surgeons, Staff nurses and other para 
medical workers for their support. 
I thank my parents, family, friends for their help and support. 
Last but not the least I would like to thank my patients with gratitude for 
their cooperation during study and for teaching us the art of medicine and 
inciting us to learn more. 
 
 
 
 
 
 
 
 
  
 
 
 
 
CONTENTS 
TITLE                    PAGE NO: 
 
I. INTRODUCTION       01 
 
II. REVIEW OF LITERATURE     02 
 
III. AIM AND OBJECTIVES                                                   70 
 
IV. MATERIALS AND METHODS       71 
 
V. RESULTS AND DISCUSSION                        74 
 
VI. CONCLUSION       120 
 
VII. ANNEXURES        
 
 BIBILIOGRAPHY 
 PROFORMA 
 CONSENT FORM 
 ETHICAL COMMITTEE APPROVAL LETTER 
 MASTER CHART 
 KEY TO MASTER CHART 
 
ABBREVIATIONS 
 
SHT                 SYSTEMIC HYPERTENSION 
DM                  DIABETES MELLITUS 
CVA                CEREBRO VASCULAR ACCIDENT   
TIA                  TRANSIENT ISCHEMIC ATTACK 
MI                    MYOCARDIAC INFARCTION 
ECG      ELECTRO CARDIO GRAM 
EEG                 ELECTRO ENCEPHALOGRAM 
CT                   COMPUTERISED TOMOGRAPHY 
MRI                 MAGNETIC RESONANCE IMAGING  
ADL                ACTIVITIES OF DAILY LIVING  
FLP                  FASTING LIPID PROFILE 
SUA                 SERUM URIC ACID  
CRP                 C REACTIVE PROTEIN 
ATP                 ADENOSINE TRI PHOSPHATE 
ESR                  ERYTHROCYTE SEDIMENTATION RATE 
CAD       CORONARY ARTERY DISEASE 
CKD                 CHRONIC KIDNEY DISEASE 
RA                    RHEUMATOID ARTHRITIS 
SBP                  SYSTOLIC BLOOD PRESSURE 
DBP        DIASTOLIC BLOOD PRESSURE 
IL       INTERLEUKINS 
TNF                TUMOUR NECROSIS FACTOR 
DVT       DEEP VEIN THROMBOSIS 
AIMS AND OBJECTIVES:   
 
1. TO STUDY THE BIOCHEMICAL PARAMETERS URIC ACID 
CRP ESR FIBRINOGEN IN ISCHEMIC STROKE PATIENTS AT 
GOVERNMENT STANLEY HOSPITAL 
2. TO ASSESS FUNCTIONAL OUTCOME IN THESE PATIENTS 
USING BARTHEL INDEX AT ADMISSION AND AT 
DISCHARGE 
 
MATERIALS AND METHODS 
 
PLACE OF STUDY: 
 
 DEPARTMENT OF GENERAL MEDICINE,  MEDICAL OPD, 
MEDICAL WARDS AND IMCU, STANLEY MEDICAL COLLEGE AND 
HOSPITAL, CHENNAI. 
 
DURATION: 
 
JAN 2014 TO SEP 2014. 
STUDY DESIGN: 
 
 PROSPECTIVE  OBSERVATIONAL STUDY 
 
SAMPLE SIZE: 75 
 
PATIENT SELECTION: 
 
1. ANY PATIENT COMING WITH SYMPTOMS SUGGESTIVE OF 
STROKE TO MEDICAL OPD MEDICAL WARDS AND IMCU.  
2. Proven by Imaging as Ischemic Stroke. 
 
EXCLUSION CRITERIA: 
1. Hemorrhagic stroke patients 
2. Patients with any source of Sepsis /acute infectious 
Disease 
3.  Patients presenting after 72 hours of onset 
4. Patient with Ischemic Heart disease 
5. Patient with any form of Arthritis   
6. Recent Trauma burns Surgery  
 
METHODOLOGY: 
Patients coming with symptoms suggestive of Stroke to 
OPD/admission unit/IMCU from Jan 2014 to September 2014 
are included in the study keeping in mind the exclusion 
criteria mentioned above. Patients will be subjected to 
symptom analysis, clinical examination, laboratory 
investigations and Imaging studies. The final analysis will be 
made at the end of the study to achieve the fore mentioned 
goals. 
 
CONCLUSION: 
CRP apart from being an inflammatory marker has also been found to be 
a   highly sensitive, non specific and an independent risk factor for prediction of  
Ischemic stroke. Similarly ESR, fibrinogen, Uric acid have also been found to  
be useful as early indicator of prognosis in Stroke patients. 
 
         The present study is done without any haste involving the above four 
 parameters to predict the outcome among stroke patients. This study correlates 
with the previous studies done by eminent people as quoted by my citations 
  
        Inclusion of these tests in patients with acute stroke provides clinicians  
with a low cost and useful way to predict functional outcome after ischemic  
stroke, as measured by Barthel index which has been proved to have a strong  
correlation with inflammatory markers. 
 
KEY WORDS: ISCHEMIC STROKE, INFLAMMATORY 
MARKERS, BARTHEL INDEX, FUNCTIONAL OUTCOME. 
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INTRODUCTION 
Stroke is medical emergency presenting with clinical symptoms & signs 
of disturbance of cerebral function, with symptoms lasting more than 24 Hrs or 
leading to mortalilty. Among All neurological diseases of adult life, the 
Cerebro-vascular ones clearly rank as the first in frequency and importance. 
Stroke also entails a high socio-economic burden due to increased 
morbidity and mortality. Ischemic strokes account for >80% of total stroke 
events. Biochemical Modalities will be a low cost and useful way to predict 
functional outcome after ischemic stroke 
Uric acid is an important antioxidant  increased in ischemia thereby 
conferring protection against free radical injury. 
CRP and ESR are the earliest acute phase reactants to increase during the 
inflammatory response &  independent predictors of short term stroke outcome. 
Atherosclerosis is an inflammatory process and effect of CRP is self explained. 
Combining Measurements of Cholesterol and CRP enhances the predictive 
value of CRP. 
Fibrinogen has a direct relationship in ischemic stroke and and its 
increasing levels is associated with marked reduction in cerebral blood flow. 
Inclusion of these tests in patients with acute stroke provides clinicians with a 
low cost and useful way to predict functional outcome after ischemic stroke 
which in turn is measured by Barthel index. 
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    REVIEW OF LITERATURE 
STROKE 
 DEFINITION: “Rapidly developing clinical signs of focal(or global)  
disturbance of cerebral function with symptoms lasting 24 hours or longer or  
leading to death with no apparent cause other than of vascular origin”.  Stroke  
manifests by various neurological signs and symptoms depending on extent,  
area of involvement and the underlying causes. These include coma,  
hemiplegia, paraplegia, monoplegia, cranial nerve palsy, speech disturbance and  
sensory impairment etc. Of these hemiplegia is the most common presentation,  
seen in about 90% of patients. 
 
Epidemiology 
A WHO collaborative study in 12 countries showed that the incidence rates 
of stroke ranged from 0.2 to 2.5 per 1000 population per year. Analysis of data  
on various studies shows that about 2 % of cases in hospital, 4.5 % medical  
patients & 20 % of admissions in neurology are due to Stroke. The main  
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defence modality of prevention of stroke is identification & proper management  
of  Risk factors. 
 
INCIDENCE AND PREVALENCE OF STROKE IN INDIA: 
 
Stroke burden of a community is best reflected by the incidence. Two incidence  
studies conducted in late sixties and early seventies have been reported. There is  
only one well defined population based study from Vellore in South India by  
Abraham, Daniel (1972) and Sunder Rao (1973). This was conducted in  
two phases. In the first phase during 1968 -69, total urban and rural population  
of 258,576 was studied. The prevalence rate was more in Vellore town than in  
rural areas and the same increased with age. Subsequently, between 1969 & 71, 
the population was kept under surveillance and at the  end of 2 years,  
prevalence and annual incidence rate of 84 and 13 respectively per 1,00,000  
population was found.  
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The second study was earned out as a part of WHO collaborative study in 
Rohtak, Haryana between 1971 and 1974. The incidence was 27 per 100000.  
Though various prevalence studies were already done, prevalence by 
definition misses those who died or recovered from stroke. As the proportion of 
cases that either die or recover from stroke is more than 60%, the prevalence  
figures tend to underestimate the burden of disease by a fair margin. In one  
study overall range was 90 to 222 per 100,000 (TIA and death not accounted) 
Ischemic stroke from thrombosis and embolism constitute between 47.3% and 
82.75% of all strokes. The incidence of hemorrhagic stroke was between 13.6%  
and 37.9% of all stroke cases. It is found that stroke is fairly common in  
young Indians < 40 years since they constitute 18.8 to 32% of all stroke cases. 
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ANATOMY OF CEREBRAL CIRCULATION
 
 
CIRCLE OF WILLIS 
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AREA OF BLOOD SUPPLY OF BRAIN  
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PHYSIOLOGY OF CEREBRAL CIRCULATION & 
CEREBRAL METABOLISM: 
 The normal fuctions of brain are solely dependent upon a relatively constant 
supply of oxygen and glucose from the blood perfusing it(55-70 ml\100 gram of 
brain\minute). 
 A fall in cerebral blood flow <8-9 ml\100 gram\minute results in ischaemia or 
infarction regardless of the duration. The state of hypoperfusion of the 
brain(CBF btn 8-23 ml/100gm/min) is called as “ISCHEMIC PENUMBRA”. 
 Conversely in the region of cerebral ischaemia, there is paralysis of 
“autoregulation” & the microvasculature is non reactive to pressure changes, the 
cerebral vasculature in this ischaemic zone becomes permeable to protein and 
fluid leaks in the vicinity(“extracellular cerebral edema”).Thus cerebral infarct 
is not the mere result of ischaemia from occluded blood vessels, but an end 
result of a series of highly complex modifying agents 
CLASSIFICATION OF STROKE: 
A) CLINICAL CLASSIFICATION: 
1. Completed stroke: this is rapid in onset with persistent neurological deficit 
which does not progress beyond 96 hours. This term is applied to the temporal 
profile of the stroke syndrome in which the deficit is prolonged and often 
permanent, causing demonstrable parenchymatous changes 
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2.Transient Ischemic Attack: characterized by sudden focal cerebral or mono 
ocular function loss where symptoms last for < 24 hrs & It is also secondary to 
inadequate blood supply to cerebrum, ocular structures due to arterial 
thrombosis or embolism. 
3. Reversible ischaemic neurological deficit:the deficit resolves without any 
residual deformity within a period of 1 to 3 weeks. 
B). National institute for neurological disorders and stroke (NINDS).  
NINDS has devised sub classification of ischemic stroke as per their pathology, 
clinical criteria & the vascular territory. 
i. Clinical: cardioembolic, lacunar infarction. Atherothrombotic 
ii. Mechanism:, Embolic, hemo-dynamic, Thrombotic 
iii. Vascular territory: Internal Carotids, MCA (middle cerebral), ACA (anterior 
cerebral), Posterior cerebral, Vertebral or Basilar. 
C). Oxfordshire stroke subtype classification 
i. Primary intracerebral hemorrhage 
ii. Total anterior circulation infarct constitutes 17% of all ischemic strokes. 
iii. Partial anterior circulation infarct constitutes 24% of all ischemic strokes. 
iv. Lacunar infarct constitutes 25% of all ischemic strokes. 
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v. Posterior circulation infarct constitutes 24% of all ischemic strokes 
STROKE RISK : 
Risk factors identification for stroke as well as awareness is of paramount 
importance as it helps in prevention of stroke. There will be slight difference in 
risk factors for infarction &haemorrhage.  
The common risk factors are listed below. 
Non-modifiable   Modifiable 
Age     Hypertension 
Sex     TIA  
Race/ethnicity   Carotid artery disease 
Genetics    Heart disease 
DMT2 
Smoking 
Dyslipidemia 
Obesity 
Ethanol 
Hyperfibrinogenemia, Homocysteinemia 
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1) Blood pressure : Hypertension is a major risk factor for stroke, whether 
hemorrhagic or not. About 40 percent of stroke is due to a SBP > 140 mm Hg. 
2) Smoking : The Multiple Risk Factor Intervention Trial data showed smoking 
is directly  having relation with stroke the same way it has to coronary heart 
disease.  Framingham study showed threefold increase of ischemic strokes in 
smokers as compared to non-smokers. The effect was greater at younger ages 
and paralleled  the number of cigarettes smoked. 
3) Obesity: BMI is predictive of stroke among smokers & non smokers. BMI > 
25 kg/m
2
 and smoking is responsible for sixty percent strokes in men until 65 
yrs of age. 
4) Diabetes Mellitus: Another widely accepted risk factor for stroke as a whole, 
and particularly for ischemic brain infarct, is diabetes mellitus. In the 
Framingham study it was the sixth most important predictive factor for stroke. 
5) Transient Ischemic Attacks : By and large one might expect that after 2-4 
years, one out of six patients with TIA would have suffered a thrombotic stroke. 
6) Cardiovascular Disease : Electrocardiographic changes of left ventricular 
hypertrophy raises risk of ischemic event by ten times, nonspecific ST23 
changes by four times and Cardiac failure by nine fold according to the 
Framingham study.  
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Hypertension and peripheral vascular disease, myocardial infarction, cardiac 
arrhythmias, valvular and congenital heart diseases are the predisposing factors 
of embolic type of stroke. Those with chronic fibrillating atrium are 5 to 7 times 
more liable to embolic stroke than age matched population with normal cardiac 
rhythm. Mitral valve prolapse, valve prosthesis, Endocarditis, congenital heart 
disease are all important causative factors for embolic stroke. 
 
PATHOPHYSIOLOGY OF STROKE 
From the stand point there are two processes: 
1) Ischemia, & infarction due to decrease or loss of vascular supply results in 
loss of oxygenation to brain. 
2) Disruption of Cerebral vessels leads to hemorrhage 
IN ACUTE ISCHEMIC STROKE 
The pathophysiology of cerebral damage from vascular occlusion has two steps: 
1) Haematological &Vascular events that results in reduction initially and 
further alteration of local blood flow to brain. 
B) Ischemia induced changes at cellular level mechanics causes death of 
neuronal cells, glial tissue & supportive cerebral cells.  
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The molecular level changes due to cerebral ischemia are changes that happen  
in cellular signalling, transduction of signal, metabolism & gene  
regulation / expression. 
 
 
All shaded boxes shows major changes that happen in ischemic stroke. 
Energy availability decreases in stroke, so membrane ionic primes fail.   
The raise in ECF potassium reaches levels adequate to release  
13 
 
neurotransmitters like glutamate & aspartate that are excitotoxic & also  
stimulates Na/Ca channels coupled to glutamate receptors that can help in  
development of cytotoxic edema. The influx of Ca through Ca channels raises  
free cytosolic calcium which is responsible for mitochondrial Ca overload. ATP  
production ceases & extensive cellular proteins, nucleic acids phospholipids  
breakdown due to Ca2+ mediated activation of proteases, endonucleases &  
phospholipases. Free radicals formed in this processes contributes to lipid  
peroxidation, nuclear DNA and protein toxic changes & cellular damage (a.k.a  
apoptosis/ necrosis). 
When blood flow to cerebrum is around 10-15 ml / 100 gram/ ml, it  
deprives  neuronal tissue of substrates & O2 needed for oxidative processes. In  
minutes once ischemia sets, demand is more than the brain‟s ATP synthesising  
capacity anaerobically from its meagre glycogen stores. Hence high energy  
phosphates  & substrates for their production are depleted. Lactate accumulates  
at the beginning of ischemia. H+ ions toxicity and its ability to facilitate free  
radicals can cause  injury to astroglial tissue. 
Energy dependent mechanisms when they fail causes worsening of ion 
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Gradients in membrane, opening of ion channels & equilibrium state of most 
Intra & extra-cellular ions leads to Anoxic depolarization. Hence K+ ions leave  
the cell, Na, Cl & calcium ions enter cells. Various neurotransmitters are  
effluxed in concentrations that are toxic. There is Calcium mediated activation  
of phospholipases, in turn it hydrolyzes glycero-phospholipids to free fatty acids  
& this in turn facilitates free radical peroxidation of other membrane lipids. It  
catalyses activation of proteases that lyses structural proteins and activates nitric  
oxide synthase to begin free radical mechanisms. 
Pathogenesis of moderate ischemia includes several compensatory  
mechanisms, which plays a role in maintaining normal concentrations of  
Adenosine Tri phosphate, membrane ion gradients & viability of cell. 
50% reduction of Blood flow to brain decreases electro-encephalographic  
activity, and only slightly higher ischemia completely blocks synaptic level  
transmission which leads to an isometric electro- encephalogram.  
The slight increase in membrane K+ion conductance can hyperpolarize  
pre & post-synaptic membranes, hence decreasing release of neurotransmitters  
& the postsynaptic receptors responsiveness to neuro-transmitters. Various  
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mechanisms that are responsible for an increased K+ ion conductance involves  
modulations in ATP regulated and Ca regulated channels. 
In spite of these compensatory pathways that compromise physiological  
activity to decrease energy utilization thereby preserving viability of cells, cell  
necrosis happens when moderate ischemia extends for few hours. 
Calcium ion homeostasis dysregulation features mainly in the lethal  
effect in cells of both moderately and severely ischemic brain. In moderate  
ischemia there is the partial conservation of energy dependent mechanism  
which regulates calcium ion concentrations inside the cell. This is different from  
the depletion of ATP and the complete loss of calcium homeostasis in severe  
ischemia. Hence blockade of channels in the membrane permeable to calcium  
pharmacologically may decrease calcium within cells to less than toxic levels in  
moderate ischemia alone. 
Of the many causes of ischemic strokes, thrombosis – complicating 
atherosclerosis of intra and extra cranial vessels ultimately accounts for most of  
the cases. The damage that atherosclerotic thrombosis causes to the brain is  
determined by the available collateral circulation, the speed of thrombotic  
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occlusion and by embolism distal to the thrombus. There is a tendency for  
atheromatous plaques to form at branching and curves of the cerebral arteries.  
The most frequent sites are: 
i. Internal carotid artery at its origin from the common carotid 
ii. Cervical part of vertebral arteries and at their junction to form basilar artery. 
iii. In the stem or at the main bifurcation of the middle cerebral arteries. 
iv. In the posterior cerebral arteries as they wind around the midbrain. 
v. In the anterior cerebral arteries as they pass anteriorly and curve over corpus 
callosum. 
PATHOPHYSIOLOGY OF THROMBOTIC STROKE 
The process of thrombus formation involves interplay between three  
components,  the endothelium, circulating platelets and a series of biochemical  
events that constitute a „coagulative cascade‟. 
When atherosclerosis is the primary condition, thrombus formation  
usually begins with a localized injury to the endothelium. The endothelium  
overlying a plaque suffers from damage from hemorrhage or necrosis of vessel  
wall secondary to an alteration of the vasovasorum. Thrombus forms fibrin and  
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platelet adhere to the endothelial surface and leads to partial or complete  
occlusion of the lumen. In the process aggregates of platelets are attracted to the  
site, partly through the action of prostacyclin. Vasomodulin on the surface of  
the endothelium with protein C, which normally inhibits the formation 
of fibrin through its interaction with thrombin is reduced at the injured site and 
induces clotting. Homocystine has similar effect and is believed thereby to  
promote thrombosis. Circulating platelets increase in number locally, enlarge,  
and become more adherent to one another and to the injured vessel. As they  
aggregate they discharge their granules. This process is stimulated by  
thromboxane A2, which is synthesized in the injured vessel wall. The third  
component coagulation cascade involves the interplay of series of factors 
that result in the formation of thrombin and the conversion of fibrinogen to  
fibrin. Involved in this process are changes in a number of natural  
anticoagulative products like  heparin cofactor2, anti-thrombin iii, protein C &  
protein S. A deficiency of any of these factors may predispose to in-situ  
thrombosis within either the arterial or venous systems. 
The middle cerebral artery stem, the major vessels forming the 
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 Circle of Willis ,the basilar , the vertebral arteries gives up to 100 to 300  
micrometer diameter  branches which penetrates deep white and grey matter.  
These vessels may be thrombosed by athero-thrombotic mecahnisms at its  
origin or by lipo-hyalinotic thickening mediated infarcts referred to as 
 LACUNES. They range in size from as small as 3 to 4 mm to 1 to 2 cm. 
Embolism is one of the common causes of ischemic stroke. Heart is the 
common source of emboli. Among the cardiac causes, rheumatic valvular heart  
disease with atrial fibrillation is the commonest cause. Myocardial infarction  
can cause embolism. Tiny septic emboli form multiple abscesses in brain in  
infective endocarditis. Paradoxical embolism from systemic circulation occurs  
in congenital heart disease with  shunt or even in patent foramen ovale. Post  
surgery embolization is a high risk in intracardiac surgery and prosthetic valve  
replacement. Atrial myxoma results in tumor  emboli. Mitral valve prolapse and  
mural thrombus can cause embolization.  
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EVALUATION OF PATIENT WITH STROKE: 
Of all those who have stroke only about one third of them are aware of  
the  symptoms. When these symptoms are identified, assessment must start with 
Evaluating the patients‟ ABC‟s of resuscitation. Ventilation, circulation 
abnormalities that need immediate interventions are generally rare at the time of 
stroke. 
In hospital adequate triage is essential. The general assessment includes  
an adequate history, examination, Spo2 monitoring; glucose, electrolytes, Full  
blood count, coagulation tests, ECG and CXR. 
The neurologic examination should include assessment of dysphasia, 
hemiparesis or sensory loss, hemianopia and other signs of focal deficits. Any  
focal deficit if present which has an abrupt onset in the absence of trauma  
indicates stroke.  
But further evaluation is carried out in the form of imaging  studies, for  
(a) precise localization of ischemia or haemorrhage and (b) to ruling out other  
mimickers of stroke like seizures, hypoglycaemia, tumor, migraine &  
HTN encephalopathy. 
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CLINICAL FEATURES OF ACUTE STROKE 
1)Athero thrombotic stroke 
Ischemic type of stroke can be thrombotic or embolic in etiology. The  
main etiological factors are Systemic hypertension & atherosclerosis. SBP  
(systolic) is as important a  risk factor as DBP (Diastolic pressure). DM,  
dyslipidemia are other risk factors. 
Most of the times there is a preceding episode of Transient ischemic 
attacks  lasting for a period of < 10 min which indicates thrombus of the major  
vessels that is evolving. In embolism there are numerous episodes of TIAs  
extending  for several hrs causing complete deficit. Twenty percent of infarcts  
that succeed Transient ischemic attacks happen less than one month after the  
initial attack while fifty percent% happens in one year. 
Transient ischemic attacks can be for a few seconds or up to twelve to  
fifteen  hrs; mostly they last from two to 15 mins. Between attacks, there may  
be no neurological deficits. In most of the patients, attacks has no relation to  
activity or position, though they are likely to occur when the patient is mobile  
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than when they are resting. Main pathology is closely associated with vessel  
stenosis, atherosclerotic ulceration & thrombotic plaque formation. 
Though TIA‟s refers to any abrupt onset focal neurologic deficit which 
disappears completely in < 24 hrs, this term is very broad as it does include  
other entities that are not always  due to  ischemia per se like an epilepsy or a 
migraine with CNS symptoms. Hence it is best to consider focal and  
completely reversible, ischemic episodes extending from minutes to an hour as 
Transient ischemic attack. Ischemic signs extending > 24 hrs and < than seven  
days is known as RIND (reversible ischemic neurologic deficit). 
Stroke in Evolution - indicates neurological deficit which progress or has  
fluctuating course when the patient is in observation, where as „completed  
stroke‟ means there is no further deterioration. Such Fluctuation in the  
neurological status are mostly due to thrombus or emboli moving, breaking &  
disappearing from one vessel to another, and are caused by repeated artery to  
artery embolization / collateral flow which fluctuates. 
It develops mainly in one of the following ways: 
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1. stroke in evolution - There could be  a single attack evolving in a few 
hours  
2. stroke in evolution - “stuttering” progression extends  over several hrs or  
longer than a day. 
3. A partial stroke which occurs but recedes temporarily for few hrs after  
which there is rapid worsening to completed stroke. 
4. More confusing one is a “slow stroke” which evolves over weeks and is  
secondary to long term hypo-perfusion. 
Occurrence of stroke during sleeping hours or immediately after getting up is  
another feature of thrombotic type of stroke. At the beginning symptoms like  
vomiting, headache, and LOC are less frequent than with intracerebral  
hemorrhage. The headache in ICH/SAH is more violent associated with neck  
stiffness. Based on specific territories of cerebral supply involved a number of  
syndromes are described. MCA involvement is the most common that results in  
complete or partial motor hemideficit, hemi-anaesthesia,  
hemainopia(homonymous type) and language deficits. 
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2) Lacunar infarcts 
It constitutes ten to fifteen percent of all types of strokes. They are due to  
infarcts in the deeper parts of the cerebrum secondary to  lipohyalinosis or  
microatheromas in  the deep penetrating vessels giving supply to internal  
capsule, basal ganglia, &  paramedian region of brainstem. These are very small  
and not  seen in 1/3
rd
  of the subjects. Types are pure motor , pure sensory  
stroke, Clumsy Hand dysarthria syndrome, ataxic hemiparesis and pseudobulbar  
syndrome. Death is uncommon. 
3) Embolic infarction 
Most of the times, embolic source is cardiac in origin which could be due  
to (AF) atrial-fibrillation Rheumatic or valvular or atherogenic cardiac  
illness, MVP.  Major sites are obstruction in the MCA, at the upper division and  
the PCA, at the bifurcations.ACA occlusion is uncommon.  
Stroke can cause a severe deficit that improves rapidly due to dissolution of the  
embolus. It is the most important reason for a single evanescent event.  
Sustained CNS deficits depend upon the regions involved. Emboli that are  
25 
 
small can occlude the MCA branches producing focal disorders like - Receptive  
aphasia, motor aphasia, monoplegia. It is thought of in younger individuals  
where consciousness is well present even after higher grade of neurological  
deficits. 
INVESTIGATIONS: 
Computerised Tomography: 
It is one of the important investigations in Stroke patients.    
Rapid, less expensive & easily available. 
Drawback is low sensitivity. 
 Middle cerebral artery region infarct identification is around 70% in the  
first six hrs , though changes in the deep grey matter nuclei like lentiform  is  
identifiable in < 1 hr of occlusion in around sixty percent of subjects.  
The main role of Computerised Tomography in emergency setup:   
1. Rule out ICH, important to avoid unnecessary thrombo-lysis  
2. Identify early subtle signs of infarction 
3. Rule out other cerebral tumours which mimicks stroke 
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The first sign identified is a hyperdense segment of an artery, reflects vessel   
thrombosis or emboli. It is well seen in MCA (Middle Cerebral Artery  
Hyperdense sign).  
Hyper-acute stage ( 1-3 hrs) 
In the initial hrs depending on the site of block and collateral flow a few signs  
are noted.  These include: 
Loss of differentiation of grey & white matter, and reduced attenuation of the  
deeper nuclei - lentiform nucleus, seen in seventy five percent pts at three hrs 
 
 Loss of insular ribbon sign.  
One week 
Significant mass effect causes 2
ο
 damages in those with larger infarcts.  
2-3 weeks 
Petechial haemorrhages with the cortex seen 
Months 
Gliosis establishes & seen as a low density region. 
Computerised Tomography guided Angio: 
1. Identification of intracranial vessel thrombus thus guiding clot retrieval or  
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thrombolysis. 
    2.  Establishing etiology and assessing limitations in endo-vascular  
treatment. 
MRI 
MRI is more time consuming and less available than CT, but has significantly  
higher sensitivity and specificity in the diagnosis of acute ischaemic infarction  
in the first few hours after onset. 
T-1 IMAGE 
Low intensity signals roughly mirrors high T2 / FLAIR signal 
High intrinsic T1 signal due to laminar cortical necrosis seen as a ribbon 
mostly > two weeks 
 
DWI 
Diffusion restriction is usually seen within minutes once ischemia sets in and 
it depicts the Infarct site well  
T2-weighted imaging and FLAIR 
Low sensitivity compared to Diffusion Weighted images in the initial hours 
Initially there is loss of normal signal void in large arteries.Within six to twelve  
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hrs, there is high signal within the infarcted tissues Effacement of sulci & mass  
effect establishes- it gets maximal in the intial period. 
Fogging: between 1 - 4 weeks inflammatory cells infiltrates can decrease T2  
signal & it gets relatively iso-intense to brain parenchyma that is normal.  
GRE/SWI 
High sensitivity for haemorrhagic stroke 
TREATMENT: After the diagnosis of stroke is made, the main aim is  
treatment for prevention or reversal of brain injury. Includes the following 
(a) Medical management 
- Control blood pressure (if more than 185/110mmHg) 
- Maintain serum glucose at < 200mg/dl 
- Anti oedema measures to reduce ICP 
- Preventing infections, deep vein thrombosis (DVT), and bedsores. 
(b) Thrombolysis-intravenous or intra arterial 19 
(c) Anticoagulation- for stroke in evolution 
(d) Neuroprotection 
(e) Rehabilitation 
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In Intracerebral hemorrhage 
(a) Supportive treatment (as in ischemic stroke). 
(b) Surgical evaluation (for cerebellar hemorrhage) 
PRIMARY AND SECONDARY PREVENTION OF STROKE: 
GENERAL PRINCIPLES: 
A number of medical and surgical interventions, as well as life-style 
modifications, are available for preventing stroke. Some of these can be widely 
applied because of their low cost and minimal risk; others are expensive and  
carry substantial risk, but may be valuable for selected high-risk patients. 
Hypertension is the most significant of the risk factors; in general, all 
Hypertension should be treated. The presence of known cerebrovascular disease  
is not a contraindication to treatment aimed at achieving normotension. Also,  
the value of treating systolic hypertension in older patients has been clearly  
established. Over control of Blood pressure must be avoided, however; the  
treatment goal is to achieve normotension gradually. 
Treatment of hypercholesterolemia with statin drugs were found to lower  
stroke risk. As CAD is most important cause of mortality in those with CVD,  
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treatment of hypercholesterolemia seems prudent for both the heart and brain.  
Tobacco smoking should be discouraged in all patients. Whether or not tight  
control of blood sugar in patients with diabetes lowers stroke risk is uncertain. 
ANTIPLATELET AGENTS: act by inhibition of intraarterial platelet  
aggregate formation. Clopidogrel, Aspirin and dipyridamole are the antiplatelet  
agents used most for this purpose. 
ANTICOAGULATION THERAPY: 
There are few data to support the use of long-term warfarin for preventing 
atherothrombotic stroke, either intracranially or extracranially. Several large  
trials are in progress.  
Thromboembolism is one of the most serious complications of prosthetic 
heart valve implantation. Anticoagulation has been proven to be effective for 
preventing strokes in this situation and a greater degree of anticoagulation (INR   
of 3 to 4, depending on valve type) is recommended for prosthetic heart valve  
patients. If source of emboli is not cleared, anticoagulation must be given life  
time.  Secondary prophylaxis for ischemic stroke of unknown origin is 
controversial. Some physicians prescribe anticoagulation for 3 to 6 months  
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followed by antiplatelet treatment. 
SURGICAL THERAPY: 
Surgery is mainly for plaques at the origin of the ICA -internal carotid  
artery in the form of Endarterectomy.   
Symptomatic carotid stenosis was studied in the North American  
Endarterectomy trial Collaborators (NASCET) and the European Carotid  
Surgery Trial (ECST). It showed that there was a substantial use in patients  
with a  stenosis of >70%. In NASCET, the average ipsilateral stroke rate at two 
years was found to be 26% for patients treated medically and 9% for those 
receiving the same  medical treatment plus a carotid endarterectomy. This 17%   
absolute reduction in the surgical group is a 65% relative risk reduction  
favouring surgery. NASCET also showed a significant benefit for patients with  
50 to 70% stenosis, although less robust. ECST found harm for patients with  
stenosis in the 0 to 30% range treated surgically. 
The indications for surgical treatment of asymptomatic carotid disease  
have been clarified by the results of the Asymptomatic Carotid Atherosclerosis 
Study (ACAS), which randomized patients with 60% stenosis to medical  
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treatment with aspirin or the same medical treatment plus carotid  
endarterectomy. The natural history of asymptomatic stenosis is an  
approximate 2% per year stroke rate, whereas those patients with symptoms  
have a 14% per year stroke risk. To advise Surgery for a patient without  
symptoms is always in dispute & decided by other factors including patient age, 
preference, co-morbidities. Medical therapy for reduction of atherosclerosis 
risk factors and aspirin, 325 mg/d, are generally recommended for patients with  
asymptomatic carotid stenosis. As with atrial fibrillation, it is imperative to  
counsel the patient about TIAs so their therapy can be revised if they become  
symptomatic. 
 
CRP (C – Reactive Protein ) 
It was the first protein to be discovered which behaves as an 
acute phase reactant. It has been named for its calcium-dependent interaction  
with the somatic C-polysaccharide of pneumococci (CPS).  
C-Reactive Protein was discovered by Tillet and Francis in 1930, when they  
investigated immunological reactions  with extracts of Streptococci in 
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Pneumonia. It was found out that the serum of acutely sick patient was 
precipitated by a fraction „C‟ (non type-specific somatic polysaccharide). Once  
the event resolves, the ability of the subjects serum to precipitate CPS is lost 
and the C-Reaction material was not found in the serum of normal individuals. 
Avery et al (1941) identified that the CRP is a protein that requires Ca  
ions for  its reactions with C-polysaccharide and gave the term “acute phase” to  
represent serum drawn from acutely ill patients having  infectious disease . 
Lofstrom, (1944) identified a Quellung reaction of few strains of  
pneumococci and also noted that the factor responsible for it  was C-Reactive  
Protein. He identified CRP raise in infectious & non-infectious conditions. 
In atherosclerotic plaque inflammation is very important and it is related with 
macrophages, endothelial cells and smooth muscle cells activation &  
proliferation. 
Literature Review insist on the fact that cerebro-vascular events do  
happen amongst those without evidence of very high cholesterol levels and  
there is a need for good risk stratification methods. 
Of all risk factors know at present, hs- C-Reactive Protein, a marker of  
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low grade vascular inflammation, is among the most promising. Various studies  
do show us  that hs-C-Reactive Protein adds as a valuable prognostic tool for   
all LDL cholesterol levels and at all stages of the Framingham risk score. 
CRP is associated with Metabolic Syndrome and onset of DM. Evidence  
does show us that C-Reactive Protein independently identifies cerebral  
thrombotic episodes. It also is a good predictor of risk of stroke independent of  
the Framingham co-variates. After adjustment for BP, DM, dyslipidmeia,  
smoking,  the risk of recurrent stroke in Framingham heart study raised by 25%  
in men and 29% in women for each increasing value of CRP. Hence CRP act as  
an important means of predicting risk in addition to the one achieved by simple  
measurement of burden of atheroscelrosis. 
                  
 Pentameric structure of CRP 
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Synthesised in Liver hepatocytes and the increased release is driven by  
cytokines from macrophages (activated). The concentration of C-Reactive 
Protein can rise upto 10000 fold.CRP levels is proportionately related to  
the presence & severity of cardiac, cerbrovascular and peripheral vascular  
atheromas. 
Tumour necrosis factor, interleukin-1 and interleukin-6 also mediate  
acute phase response.61 These soluble mediators react with hepatocytes and can  
influence the expression of specific genes in hepatocytes which are responsible  
for synthesis of certain proteins that are part of the acute inflammatory  
response. These includes all acute phase reactants like CRP, A-1 antiproteinase,  
hapatoglobin, C3 and fibrinogen. CRP is the earliest one to increase in  
inflammation. It is a protein that reacts with capsular polysaccharide  
of streptococcus pneumonia and can activate complement by classical  
pathways. 
Today, however, the best single test of acute inflammation is C- 
Reactive Protein level that can be readily quantified by nephelometry. 
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INFLAMMATORY STIMULI 
IL-1, IL-6, Tumour necrosis factor   C-Reactive Protein 
MD – monocyte derived macrophage, endothelial cellactivation, Tissue 
factor, and adhesion molecules etc. 
 
 
 
        Atherosclerosis 
 
 
Complexion of CRP to cell membrane 
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C-Reactive Protein has profound pro-inflammatory property. It can also 
Promote the synthesis of monocyte chemotactic protein-1 (MCP-1) thereby  
activating recruitment cascade. 
The average circulating levels is 0.8 mg/l. 
90%  <3 mg/l 
99% <10mg/l 
 
The rate of synthesis and secretion of C-Reactive Protein increases in few  
hours of an acute injury, due to various humoral mediators such as  
endogenous leukocyte mediator a Pyrogen66  and  PGE (prostaglandin). It may  
reach peak values upto 300 mg/ml in less than 1-2 days. It is a part of Pentraxin  
family of proteins with a mol. weight of 105500 Da. It consists of non  
glycosylated identical positive polypeptide units, associated non covalently 
in a disc configuration, forming a  pentameric (cyclic) symmetry. The  
structure & the sequence of the amino acid subunit are different from other  
known proteins except amyloid P. 
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FUNCTIONAL PROPERTIES OF C-REACTIVE PROTEIN 
C-Reactive Protein causes precipitation of soluble ligand and agglutination of   
Particulate ligand through its calcium dependent or its polycations  
binding venues, it is a strong activator of the complement pathway (Classical) 
beginning in C1q. Through Complement activation, there happens adherence 
reactions and fixation of C5b-C9 complexes and in the end lysis when the  
ligand is on cell surface. 
Complement split fragments, which gets activated in the fluid phase are  
formed. C-Reactive Protein like Anti-bodies can attach to the ligands, carry  
out opsonisation, phagocytosis & begin cell damage. Of all the hypothesis given  
now it is known that atherosclerosis is an inflammatory process and that 
C Reactive Protein has a profound pro-inflammatory effect. Using MCP-1  
activation as an assay, Edward T.H. Yeh, showed that both lipid lowering  
agents can block C-Reactive Protein mediated MCP-1 stimulation. 
Additional Role of CRP includes: 
1. T-lymphocytes selective binding and modifying its functions. 
2. Platelet Aggregation & activation suppresion. 
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3. Phagocytes activity and mobility enhancement. 
 
C-Reactive Protein was found out in the lesion which was associated with  
C3 deposition, angiotensin-1-receptor [ATI-R], vascular CAM-1 and  
expression of  collagen. These enlighten us that C - reactive protein in vivo has  
a Pro- atherogenic role. 
However, the most important  role played by C - reactive protein is to  
recognize the toxic autogenous materials from dead & damaged tissues in  
plasma, to  facilitate their clearance by binding & detoxifying them. 
CLINICAL IMPLICATIONS IN CRP MEASUREMENT: 
->Absence of circadian variation  
->Diet doesn‟t alter its levels (patient need not fast) 
Measuring the levels of cholesterol & C - reactive protein enhances the 
predictive value of C-Reactive Protein. When both are high overall risk of   
CVA rises up to 9 times on comparing to those with decreased C-Reactive  
Protein & cholesterol. 
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CRP synthesis is not altered by any therapies, unless these affect the 
underlying disease processes that provoke the acute phase reaction. The only 
scenario that alters the normal C-Reactive Protein levels is liver failure. 
DETECTION AND MANAGEMENT OF INTERCURRENT INFECTION 
Increased level is a useful indicator of possibility of  infection in otherwise  
normal subjects or individuals with a primary condition that predisposes 
to infection. adequate therapy of the infection source leads to a prompt fall in 
CRP levels on the other hand if the levels remains the same it shows continuing 
activity of the underlying disease process. 
 
CONDITIONS ASSOCIATED WITH MAJOR RISE OF CRP 
Allergic complications of infection, Erythema nodosum leprosum 
Rheumatic fever 
IBD 
PMR (Polymyalgia Rheumatica) 
Rheumatoid and Psoriatic arthritis 
Ankylosing spondylitis, 
FMF  
Graft rejection, Post transplantation. 
Malignancy- sarcoma, lymphoma, 
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Necrosis Myocardial infarction, tumour Embolization  
Pancreatitis 
Burns, Traumatic fractures 
 
EPIDEMIOLOGICAL STUDIES 
Curb et al. had done a study based on serial review of C-Reactive  
Protein measured from 259 thromboembolic stroke cases and by comparing  it 
with 1348 people as control population. It showed positive association of CRP 
with thrombotic and embolic stroke. 
Weinbeck et al. studied 127 patients with first ischemic stroke and 
compared C-Reactive Protein levels at admission, 24 hours and 48 hours. They 
found that C-Reactive Protein levels at 12 and 24 hours are independent 
predictors of unfavourable outcome. 
Muir et al. studied 228 ischemic stroke admissions. Median follow up 
was 959 days. Geometric mean C-Reactive Protein concentration was > 10.1 
mg/L. It was found that survival in those with C-Reactive Protein> 10 mg/L was 
significantly worse than in those with C-Reactive Protein < 10 mg/L (p 0.0009, 
log rank test). They concluded that C-Reactive Protein concentration is an 
independent predictor of survival after ischemic stroke. The single independent 
predictor of survival in this study was measurement of CRP within 72 hours of 
onset of symptoms. 
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Natalia et al. prospectively studied 591 men and 871 women from 1980-
82, when 196 ischemic strokes and TIAs occurred. They concluded that 
elevated plasma C-Reactive Protein levels significantly predict the risk of future 
ischemic stroke and TIAs in the elderly without being dependent on other 
cardiac risk factors. 
Di-Napoli et al assessed the relation between blood pressure and basal 
concentrations of C-Reactive Protein in the first 24 hours after onset of stroke. 
The associations were calculated based on regression methods. They found 
that for each 10 mmHg raise in SBP, DBP, MAP and the odds of a greater value 
of  CRP raised as well  by 72% , 10% , 21% and 10% (significant p value) 
respectively. Thus higher SBP is definitely having a significant association with 
increasing levels of CRP in patients of ischemic stroke. 
 
 
THE ERYTHROCYTE SEDIMENTATION RATE (ESR) 
Otherwise known as Westergren ESR, is the rate at which there is 
sedimentation of RBC‟s within 1 hr. It is another inflammatory marker. It 
utilises blood that is anti-coagulated and kept in a vertical tube named 
Westergren‟s tube and measures the rate of fall of RBC then reported as 
millimetre/hour. 
ESR is an indirect measure of inflammatory response in contrast to CRP 
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Red blood cells do not clump together due to their negative charge which 
repel each other normally 
Positively charged plasma proteins neutralize the negative charge of RBCs, 
resulting in them stacking as roleaux or tyres. 
Roleaux has a greater surface to mass ratio compared to a single RBC hence 
faster sedimentation 
It is also a very good means of measuring morphology of RBC as well as that of 
plasma protein composition and concentration. Concomitantly there is a raise in 
levels of C-Reactive protein. 
Alteration in surface area of RBC and its density changes ESR. It makes roleaux 
formation difficult and hence a disproportionately low erythrocyte sedimation 
rate as in sickle cell disease & hereditary spherocytosis. 
Doubts if any discrepancy must be corrected by assessment of the various  
determinant factors of Erythrocyte Sedimation Rate. 
In 1897 it was first found and used by Edmund biernacki a pathologist.  
Hence it is also called as BIERNACKI’s Reaction.  
Advantages : many a times helps in diagnosing diseases like 
-> Multiple Myeloma 
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-> Polymyalgia Rheumatica 
-> Autoimmune Diseases 
-> SLE, RA, IBD, CKD where its values can be > 100 millimetre/ first hour. 
-> Koch‟s disease, cardiac illness. 
-> Infective endocarditis 
Stages in erythrocyte sedimentation: 
a) First stage   - 10 min - Rouleaux formation 
b) Second stage - 40 minutes – settling/ sedimentation  
c) Third stage -10 min – packing stage settling slows and cells pack in the 
bottom of the test tube. 
Reference Values: millimetres per hr 
AGE  20 55 
Males 12 14 
Females 18 21 
 
ESR is an easy and affordable blood test for monitoring inflammatory 
response and it also helped in prediction of outcome of stroke patients in the 
shorter duration. Erythrocyte sedimentation rate > 28 millimeter/hour reflects a 
worse prognosis. 
An association was established between Erythrocyte sedimentation rate, 
Fibrinogen and cerebro-vascular flow. It showed that higher Erythrocyte 
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sedimentation rate during acute stroke can indirectly indicate a markedly higher 
rise in fibrinogen levels and a marked decrease in blood flow to cerebrum, 
resulting in worsening of lesions. 
The relationship between Erythrocyte sedimentation rate and the outcome 
in stroke patients can also represent the alterations in the usual level of natural  
occurring anti-coagulants. 
In recent times a strong association was identified between Erythrocyte 
sedimentation rate & C4b-BP protein, a HMW protein which has a site for 
attachment of Vitamin K dependent protein S, a coagulation inhibitor.  
Whenever protein S binds to C4b-BP, the former will lose its anti-coagulant 
property. Hence alterations in C4b-BP protein can result in thrombosis. 
Early raise of Erythrocyte sedimentation rate is an excellent marker of 
poorer outcome in initial period in patients with stroke.  
 
As the details obtained from this test is seen with the severe nature of 
cerebrovascular accidents at hospital entry, the nature of clinical onset, a 
sensitive & specific prediction of functional outcome can be obtained for the 
shorter-term.  
 
Hence measuring Erythrocyte sedimentation rate at the time of admission 
for patients with symptoms of stroke gives physicians with an easy cheaper and 
beneficial test when early imaging usually inappropriately estimates the actual 
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extent of cerebral infarcts and reduces the specificity of those models depicting 
functional outcome after acute Ischemic stroke. 
 
URIC ACID: 
It is an aqueous antioxidant present abundantly in Homo sapiens, forming  
up to 2/3
rd
 of plasma free radical scavengers & is efficient in neutralising OH
-
, 
H2O2
-
 radical‟s thereby preventing per-oxidation of lipids. In a number of 
organs Uric acid levels raises in ischemic events with oxidative stress. Higher 
levels act as a mechanism which protects from free radical scavenging.  
Synthesis: 
It is the ultimate product when purines are metabolised in humans.  
When compared to allantoin a soluble product produced in lower animals, UA 
is weakly soluble product of  metabolism of purines in human beings. UA levels 
are higher because of the lack of hepatic enzyme - uricase as well as due to 
reduced elimination of uric acid in urine. 
Source: 
 2/3rd Endogenous production 
1/3rd Dietary source.  
 
Metabolism: 
Seventy percent excretion is through renal mechanism and 30 % by GIT.  
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Uric acid levels in blood depend on a proper balance between: 
Purine metabolism & 
Urate rate of elimination  
Any one mechanism when affected can cause increasing levels though 
decreased elimination is responsible for increasing levels in most of the patients. 
A Uric acid- Anion exchanger URAT1 is seen in the brush border of the 
renal tissue. Another human organic anion transporter is seen to be blocked by 
drugs with uricosuric actions, while another uric acid transporter facilitates uric 
acid to be pushed out of the cell. All these transporter mechanisms are 
responsible for the secretion and re-adsorption in renal tissues. 
Uric acid secretion has a strong correspondence with the its serum 
concentration, as a slight raise in the serum levels causes a drastic increase in 
uric acid elimination. Reduced secretion in tubules occurs in patients having 
acidosis as the organic acids that assimilate compete with uric acid for 
secretion. At last, increased re-adsorption of urate distal to the site of its 
secretion is the main mechanism causing higher levels of urate in those on 
diuresis and those having diabetes insipidus. 
 
Over production : 
 exogenous (purine rich diet) 
 endogenous (increased catablolism).  
Sometimes there is a deficient HGPRTase eg: Lesch Nyhan syndrome,. 
48 
 
Blast Crisis of acute leukemias  
Cellular death due to rhabdomyolysis 
Glycogenoses types 3,4 & 7 causes hyperuricemia from breakdown of 
 Adenosine-Tri-phosphate in muscle. 
Ethanol consumption (rapid catabolism of ATP in liver & production of 
substances that competes with uric acid to be secreted in tubules.  
 
Prevalance of Hyperuricemia: 
 Higher in elderly people > 65 years 
 Sex wise distribution  
o When age <65  M: F prevalence – four times more in males 
o When age <65 M: F prevalence – three times more in male 
Courtesy: Study from Japan. 
Disability and Death  
More in patients with 
Hypertension  
Females & aged people. (etiology not known) 
Hyperuricemia is an important marker for comorbidity risk factor than a 
causative factor. 
The normal urate levels in children is lesser. (Reference range is 5mg/dl).  
Males  7 mg/dl 
Females is 6 mg/dl.  
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Sources: 
Poultry & animal products mainly organs.  
sweetbreads 
anchovies 
sardines 
 liver, beef brain & kidney 
It can be raised secondary to increasing fructose intake & decreased renal 
elimination with high purine in diet.  
 
RELEVANCE TO STROKE: 
In experimental models with animals, local Uric acid raises in significant 
levels in cerebral injury. 
As in one case: In Rat, MCA artery obstruction results in raise in cerebral 
UA concentrations to significant levels that persists for many days Post injury. 
These observations has prompted an interest in the potential impact of 
Uric acid levels in the setting of an acute event of ischemic stroke. Uric acids 
role as an independent risk predictor in vascular disease was questioned for 
several years. Various studies do indicate that elevated concentration of uric 
acid can be important in prediction of risk of stroke. Further treatment to 
decrease uric acid has shown to decrease the cardiovascular disease mortality. 
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Those with Non insulin dependent Diabetes have a 2 fold to 4 fold risk of 
showing effects of atherosclerotic disease like stroke. It is indicated that 
Increased uric acid levels is an important factor in the prediction of stroke in 
middle aged individuals with Non insulin dependent Diabetes independent of 
rest of the CV risk factors. 
This Uric acid concentration is a useful, simple marker to select and treat 
patients at risk. SUA has been recently associated with insulin resistance. 
Urate is a marker of oxidative stress. It has an important role as an 
antioxidant. It can also play the role of a peroxidant, when at greater levels. 
Whether rising urate levels in conditions related to oxidative stress like 
atherosclerotic stroke is a preventive response or the main cause is unclear. 
Through researches it is identified that hyper-uricemia mediated oxidative stress 
act as an important mechanism in Metabolic Syndrome. 
Various studies does indicate that Urate levels were markedly increased 
in those who succumbed to stroke when compared to the ones who got 
discharged thereby proving that it is useful as a marker for increased risk of 
stroke & risk stratification post stroke. Serum Uric Acid is as an Independent 
Predictor of early mortality post stroke as well as for higher vascular event 
rates. Though urates role in far from being certain, therapies to lower uric acid 
levels is definitely worthy. 
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FIBRINOGEN 
Fibrinogen – A Glycoprotein that consists of 3 pairs of non-identical 
polypeptide chains namely Aα (alpha),  Bβ(beta) and γ(gamma) chains 4. 
In the first phase of thrombus formation soluble fibrinogen is converted into 
insoluble fibrin by thrombin. Thrombin cleaves Aα and Bβ chains thereby 
releasing  fibrinopeptides, these fibrinopeptides initiate a process in which fibrin 
monomers begin to gel. These fibrin monomers polymerise to form fibrin 
polymers. This process continues and elongation of polymers causes formation 
of protofibrils. Once a critical mass of long protofibrils is established, the 
protofibrils form lateral contacts with other protofibrils thereby forming fibrin 
clot. Fibrin clot thereby potentiates formation of thrombosis. 
Various studies show us that higher levels of fibrinogen levels have a 
strong correlation with the athero-sclerotic complications namely MI & 
Cerebrovascular events. Thrombosis is found to play a significant role in both & 
Fibrinogen has an important role to play in thrombosis.3  Hence identifying the 
association between thrombosis and fibrinogen can increase the predictive value 
of this glycoprotein and suggest a different line of treatment in stroke patients.3  
Hence the study design is such as to  find out the relationship among plasma 
fibrinogen and acute stroke. Higher levels of Fibrinogen are an independent risk 
factor in aetiology of Stroke. It assists in predicting adverse events in future. 
Hence, Estimation of levels of Fibrinogen and treatment is valuable to improve 
the outcome of the patient.  
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STRUCTURE : 
DIAGRAM TO ILLUSTRATE FIBRINOGEN STRUCTURE     
 
 Liver synthesize fibrinogen and secrete it in to plasma. The molecular 
structure as revealed by Electron microscopy is a large trinodular di sulphide 
bonded glycoprotein with 2 evenly symmetric molecules. Each half has 3 
distinct polypeptide chains namely Aα, Bβ and γ chains. The molecular mass of 
whole molecule is 340000 dalton, length is 45 nm, diameter is 9 nm. Its central 
nodule i.e E –domain is 5 nm in diameter. It has the NH – 2 terminal of all six 
polypeptide chains and thus it forms the NH – 2 terminal disulphide knot.  
The outer D-domain nodules are made of the C-Terminal two thirds of 
both the Bβ and γ chains. Xray diffraction studies indicates that the Bβ, γ chain 
each form an independent subdomain within the D- domain. These two 
subdomains are located diagonally along the long axis of the molecule. Between 
the E and D domains, a stretch of approximately 120 amino acids is present 
from each of the 3 chains which form a α-helical structure - the “coiled coil 
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domain”. This part of the molecule is assisted on either side by a set of 
disulphide bonds which is the disulphide ring. This plays a major role in making 
fibrin strong & proteolysis resistant. 
The Aα chain is a 610 aminoacid polypeptide. It‟s divided in to three 
seperate domains. The first section (Aα chain - residues 1-194) has a region 
(residues 45-161) linked to the Bβ and γ chains by disulphide bonds. This 
section forms part of the α-helix or coiled coil domain. This part also has 
fibinopeptide –A (residues1-16) and the polymerization site in the E-domain.  
The middle third of the molecule (residues 240-424) is rich in apolar 
aminoacids and has ten tandem repeats each 13 aminoacids long. The region 
bridging these two sections (195-239 residues) is made up of domain which has 
high amounts of pralines and several plasmin cleavage sites.Two glutamine 
residues in the middle serves as an important receptor site for factorXIII a cross 
linking. 
  The hydrophilic C terminal third of the molecules (residues 425-610) act 
as cross-linking sites for fibronectin and α-2 antiplasmin. Residues 95-97 &572-
574 present in Aα chain act an important role in cellular adhesions. 
  The Bβ polypeptide chain has 461 aminoacids and has 3 sections. Initial 
80 residues is made of  fibrinopeptide B sequences (1-15 ) as well as a site 
which supports endothelial cell spreading and proliferation (15-42). Residues 
81-192 linked to Aα and γ chains through disulphide rings .It forms the coiled 
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coil domain. The C-terminus of the Bβ chains forms subdomain of the D-
domain which is independently folded. 
 The γ chain is 411 aminoacids long. It is divided in to 3 sections. Unlike 
the other chains, it has no fibrinopeptide at its NH2 terminal. The first 18 
aminoacids of the γ chain form the disulphide knot portion of the NH2 terminal. 
Middle segment consists of aminoacids 19-135. It also has the disulphide rings 
that connect this region to Aα and Bβ chains in the coiled coil domain. The C- 
terminal portion which has aminoacids 136-411 forms a globular sub domain of 
the D domain. In this part is the D-domain polymerization site as well as the 
Factor XIIIa cross linking sites and the binding domain for aggregation of 
platelets (400-411 residues). 
The γ chains have two forms γ and γ1. The latter contains an extended C 
terminal. It is produced by polyadenylation of the last intron of the γ gene chain. 
Studies have shown γ1 is a carrier for zymogen of factor XIII in circulating 
blood. 
SYNTHESIS: Plasma fibrinogen is synthesized exclusively by the hepatocyte, 
and the synthesis of the three chains is controlled by 3 different genes localized 
on 4th Chromosome (ch4q23-q32). T1/2 is of 72-108 hours. The turnover rate of 
fibrinogen is about 1.7-5 gm/day (30-60mg/kg/day). 
 Normal Fibrinogen levels – 233 to 496 mg/dl 
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FUNCTION: 
Fibrinogen plays the central role in three major functional processes. 
1. The soluble fibrinogen molecule is converted into insoluble fibrin during the 
process of blood coagulation. 
2. The polymerized fibrin serves helps in assembling & activating the 
fibrinolytic process, which modulates fibrin deposition and clot dissolution. 
3. Fibrinogen binds to vascular cells such as platelets, where it supports platelet 
aggregation by binding to platelet GP IIa-IIIb receptors and to endothelial 
cells, where it participates in tissue repair. 
The transformation of fibrinogen  insoluble fibrin has 3 distinct phases. 
1. Thrombin cleaving the fibrinopeptide  
2. Fibrin polymerization. 
3. Fibrin stabilization, via cross linkage by XIII a factor 
 
First up, the Arginine16- Glycine 17 bond of the Aα, the Arginine 14- glycine  
15 bond of  Bβ chain is cleaved by thrombin, resulting in the release of two 
molecules of fibrinopeptide A(FPA) and two of fibrinopeptide B(FPB) per 
molecule of fibrinogen. Fibrinopeptide release from the constituent Aα and Bβ 
chains forms a fibrin (monomer), and its constituent chains of which are now 
referred to as the α-, β- and γ- chains. The proteolytic cleavage of the FPA 
occurs prior to and more rapidly than that of FPB which is sufficient to induce 
clot formation. The polymerization process involves the reciprocal non covalent 
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interaction of molecular determinants in the fragment E region of the molecule, 
which are exposed by the removal of FPA, with complimentary binding sites 
located in the fragment D region of an adjacent fibrin monomer. The resulting 
dimer which is arranged in a half- staggered overlap, continues to grow in 
length by the staggered addition of fibrin monomers, resulting in the formation 
of a two-stranded, half-staggered polymer referred to as a protofibril, the basic 
structural unit of the fibrin clot. The half-staggered polymerization process 
brings two D domains of longitudinally aligned fibrin molecules of each row of 
the protofibril into close contact with one another, resulting in further 
stabilization of the non covalently associated fibrin protofibril. Polymerization 
continues with the formation of long, double-stranded protofibrils that 
ultimately associate laterally to form thick fibrin 9 bundles. The cleavage of 
FPB occurs mainly during the initial phase of fibrin polymerization and exposes 
determinants that are complementary with binding sites present in the C 
Terminal portion of the Alpha-chain. This interaction seems to increase the rate 
of formation of thin fibrils, as well as the lateral aggregation to form thick fibrin 
fibers. The three-dimensional fibrin matrix is completed by branching of the 
fibers at specific contact points located in the fiber bundles. Several of the 
polymerization sites within fibrin have been identified. The N-terminus of the 
fibrin α-chain participates in the interaction of the A determinant with the 
complementary binding site located in fragment D, where a segment of the γ- 
chain is known to participate in fibrin polymerization. In addition, the N-
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terminus of the fibrin β-chain participates in the assembly of fibrin by binding 
to a complementary site present in the C Terminus of the A-alpha Chain. 
 
The final stage of fibrin formation is characterized by the factor XIIIa-mediated 
formation of covalent amide bonds between the ε-amino groups of specific 
lysine residues and γ- CONH2 groups of certain glutamine residues. These 
covalent bonds are first formed at the DD contact between the γ- chains of two 
molecules. The dimerization of the γ-chain formed by bridges between Lysine 
of one γ-chain and glutamine of another is then followed by progressive 
covalent cross-linking of multiple α-chains. Cross-linking at branch points also 
produces D-trimers or D-tetramers. As a result of this covalent stabilization, the 
clot is rendered more compact and resistant to both mechanical disruption and 
dissolution by plasmin. In addition to plasma fibrinogen, the circulation blood 
contains a very small pool of fibrinogen, which is present within the platelet α-
granules. Some studies have shown that fibrinogen is synthesized by 
megakaryocyte, but more recent investigations have 10 demonstrated that 
platelets & megakaryocytes have the ability to internalize fibrinogen from 
plasma by a process mediated by glycoprotein IIb/IIIa. Plasma fibrinogen 
exhibits γ-chain heterogeneity due to differential splicing of the hepatic m- 
RNA. This heterogeneity is manifested by the presence of a minor component, 
termed γ1, in which the last four amino acids of the γ-chain are replaced by an 
extended COOH terminal sequence.        
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  The γ1-chain is not present in platelet fibrinogen and does not 
support platelet aggregation, probably due to the lack of interaction of γ1 with 
glycoprotein IIb/IIIa of the platelet. Studies of families with various genetic 
dysfibrinogenemias have provided conflicting results concerning the presence 
of the mutant fibrinogen within the platelet. While fibrinogen Paris-I was not 
found in platelets, fibrinogen Oslo-I was.       
  However, the discrepancy between the molecular and functional 
properties of plasma and platelet fibrinogen in these variants could depend on 
the ability of the platelet and megakaryocyte to internalize the abnormal 
fibrinogen. Platelet fibrinogen is secreted after stimulation and plays a role in 
supporting haemostasis. 
Fibrinogen concentration ranges from 150-400mg% which far exceeds 
the minimum concentration of 50-100mg% necessary for haemostasis. 
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DIAGRAM ILLUSTRATING ROLE OF FIBRINOGEN IN 
COAGULATION CASCADE 
  
 
 
FIBRINOGEN ASSAY. 
CLOTTING RATE ASSAY/CLAUSS ASSAYS 
The main technique was given by Von Clauss, based on the rate of clot 
formation in dilute citrated plasma following the addition of thrombin. The 
clotting of dilute plasma is inversely proportional to the plasma fibrinogen 
concentration when high concentration of thrombin is used. The quantity of 
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thrombin used must ensure that the clotting time is always dependant on the 
level of fibrinogen in plasma sample. We add thrombin (conc between 35-
200μ/ml) usually 100μ/ml for dilution of test plasma & clotting time calculated. 
Clotting end point is measured by either mechanical or photo-optical means, as 
these methods have shown excellent cross correlation and precision, results are 
compared with a calibration curve. The net result obtained is expressed in 
mg/dl. Drawbacks are that it is comparatively time consuming & needs a higher 
grade of expertise when manually done, as the endpoint is pretty difficult 
to find with an increasing dilutions of std. plasma. As this type of assay 
measures the time to formation of a detectable clot, the presence of inhibitors of 
fibrin polymerization, such as fibrinogen and 14 fibrinogen degradation 
products results in under estimation of the actual fibrinogen  concentration. 
 
At present commercial reagents as well as automated methods are being 
used by most labs and there are essential difference based on the type of 
analyzer used. Yet they are less likely to create a significant impact clinically. 
The precision is within reasonable limits when normal plasma is used and 
assessment is carried out by optical methods (typically3-7%) whereas by 
mechanical means it comes to 6-9%. 
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Ideal recommended anticoagulant for this assay is Tri Sodium Citrate at a 
concentration of 0.105-0.109m (9 parts blood with 1 part of anticoagulant). 
Blood collection must be aseptic and as fast as possible avoiding significant 
stasis. Before Estimation of fibrinogen collected samples are checked for the 
presence of clots by inversion technique .Sample with such evidences or those 
with hemolysis must be rejected. Platelets are removed ( <1lakh/Litre), by 
centrifugation. Hyperlipidemia or Hyperbilirubinemia can result in problems 
with analysis when optical methods of are used. Storage should be in room 
temperature for minimum of four hours before processing. Thawing leads to 
cryo-precipitate formation which has fibrinogen. This can affect the values. 
 
3.1.5 REGIONAL VARIATIONS IN PLASMA FIBRINOGEN LEVELS 
Several epidemiological studies have shown that normal plasma 
fibrinogen levels range from 2.3-4.0 gm/dl. The method of measurement has 
strong influence. Ernst has shown that those studies which employed the 
standard method on thrombin coagulation time (clauss assay), the mean 
fibrinogen levels varied from 2.3-4.1 gm/dl. This could not be attributed to age 
and sex because only men were selected for this analysis and patient‟s ages 
were similar. The regional variations in the fibrinogen levels are due to 
undefined environment factors and are unrelated to patient characteristics. 
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FIBRINOGEN ABNORMALITIES: 
Classified as congenital or acquired, with both groups manifesting 
quantitative defects or qualitative differences of fibrinogen molecules. In few 
instances, both quantitative and qualitative abnormalities can be present in the 
same patient. 
a) CONGENITAL DISORDERS 
i. Congenital afibrinogenemia and hypofibrinogenemia 
They are familial and cause bleeding disorders of varying severity from 
birth. Sometimes low fibrinogen may be an abnormal molecule then it is called 
hypo-dysfibrinogenemia. CT, PT and aPTT are abnormal. 
ii. Congenital dysfibrinogenemia. 
Due to synthesis of a structurally varied fibrinogen molecule which expresses 
altered properties and also exhibits an abnormal thrombin mediated conversion 
to fibrin.  
Such alterations are due to changes in few phases of fibrinogen catabolism.  
These include: 
 Fibrinopeptides release is reduced. 
 Fibrin polymerization is affected 
 Failure of polymerized fibrin to undergo normal covalent stabilization by 
factor XIIIa. 
 Abnormal interaction with platelets, endothelial cells or calcium.20 
 
63 
 
Most patients are asymptomatic. Prothrombin time is prolonged. Plasma 
fibrinogen concentration is normal when measured immunologically and the 
discrepancy between clotable protein and immunologically measured fibrinogen 
is a characteristic feature of dysfibrinogenemia. 
b.) ACQUIRED DISORDERS 
HYPERFIBRINOGENEMIA 
Various causes for elevated fibrinogen level are, 
1. Race: Fibrinogen is about 0.2gm/L higher in blacks than in whites 
2. Males: Males have a higher fibrinogen levels than females 
3. Smoking: There is a positive correlation between smoking and plasma 
fibrinogen levels; Fibrinogen level begins to fall soon after smoking is 
discontinued. The consistent observation of higher plasma fibrinogen levels in 
heavy smokers, independent of age, may be explained by two hypotheses; 
a) Smoking may lead to endothelial damage resulting in activation of the 
coagulation system. 
b) Smoking activates lung macrophages which release interleukin-6 
increasing liver synthesis of fibrinogen. 
5. Physical inactivity: There is an inverse relationship between physical 
activity and fibrinogen concentration. 
6. Diet: Diet rich in carbohydrates and fat and diet poor in ω-3 and ω-6 PUFA‟s 
and fibre are associated with raised fibrinogen levels. 
7. Excess body weight: In obese patients, both viscosity & fibrinogen levels are 
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Increased. 
8. Hyperlipidemia: There is a strong positive correlation between the 
fibrinogen & cholesterol levels, high LDL, high Lp(a) and elevated 
triglycerides. It is also consistent with an increased risk of atherosclerosis, 
thrombotic events in dyslipidemic patients. 
9. Diabetes Mellitus:  A strong association is present between HbA1c & 
plasma fibrinogen levels. In Scottish Heart Health Study, this was proved. 
10. Hypertension: Greater levels seen in hypertensives compared to 
normotensives. Despite patient being mildly hypertensive, fibrinogen levels are 
higher than normotensive controls. 
11. Ischemic heart disease: There exists a consistent relationship with the 
extent, and severity of heart disease. 
12. Left ventricular dysfunction: There is an increased risk of intracardiac 
thrombus and systemic thromboembolism in patients with poor cardiac 
function, especially in those with ventricular aneurysm and dilated 
cardiomyopathy. Thrombosis risk in patients with left ventricular dysfunction is 
increased because of increased fibrinogen levels as compared to patients with 
normal left ventricular function. 
14. Psychological and mental stress- It has been shown to increase plasma 
fibrinogen concentration. 
15. Cerebrovascular disease- Increased fibrinogen was correlated with stroke 
and TIA incidence and progression of carotid atherosclerotic lesion. Peripheral 
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vascular disease is associated with increased fibrinogen concentration. 
Fibrinogen levels have been found to be higher in those persons who are taking 
oral contraceptives and in postmenopausal age. 
18. Genetic factors- There is a significant role for it to play as genetic 
inheritability can be responsible for up to 51% of variance of the plasma 
fibrinogen level. Variation at the beta fibrinogen locus has been thought to 
affect fibrinogen concentration, because the beta gene control formation of Bβ 
chains, the rate limiting step in fibrinogen synthesis. Individuals with B1B2 
genotype who have high fibrinogen levels are at increased risk of 
atherosclerosis. 
HYPOFIBRINOGENEMIA -occurs due to  
i. Decreased hepatocyte biosyntheses due to fulminant hepatic failure, 
decompensated liver cirrhosis. 
ii. Disseminated intravascular coagulation due to increased consumption. 
iii. Use of drugs like L-asparaginase, valproic aced. 
iv. Alcohol consumption has an important effect on reducing the fibrinogen 
levels. A decrease of approximately 0.78% per 10gm of alcohol consumed has 
been noted. 
v. Fibrinolytic therapy reduced fibrinogen levels for a day or two. 
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DYSFIBRINOGENEMIA: 
Dysfibrinogenemia of liver disease: About 50% of patients with cirrhosis, 
hepatitis or hepatoma exhibit dysfibrinogenemia which is characterized 
functionally by impaired polymerization of fibrin. 
Similar changes have also been observed in hypernephroma as a part of 
paraneoplastic syndrome. 
Antibodies against fibrinogen can cause functional abnormalities of 
fibrinogen as seen in SLE, ulcerative colitis and post-necrotic cirrhosis or 
sometimes can be idiopathic. Inhibition of fibrin monomer polymerization is 
seen in multiple myeloma. 
STUDY IMPORTANCE: 
         Fibrinogen levels have increased in patients with stroke. Higher levels are 
seen in ischemic stroke compared to hemorrhagic stroke. Increasing evidence 
suggests that fibrinogen is important in the development of premature 
atherosclerosis. Levels > 350 mg/dl is a risk factor for coronary artery disease 
and stroke. There is higher risk of future CV events in those who survive from 
stroke. 
    Fibrinogen molecules bridge adjacent platelets together to form platelet 
aggregates and arterial thrombosis leading to ischemic stroke. It is a risk factor 
for further recurrences of stroke apart from age, smoking, hypertension, 
diabetes and other risk factors. Compared to altered lipid profile in the form of 
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high LDL levels, triglycerides and low HDL levels, fibrinogen is a better 
predictor of future recurrences of stroke and adverse cardiovascular events. 
Hence, fibrinogen levels are to be measured in patients with stroke at the 
earliest and to be treated. 
        Fibrinogen also interacts with monocytes/macrophages and these play a 
significant role in atherogenesis, and the binding of these two is responsible 
trigger for pro-coagulant activities. 
         Study by Shao-Yuan Chuang et al showed that in addition to hypertension 
and diabetes, fibrinogen independently predicted future ischemic stroke risk and 
altered lipid profile did not independently predict cerebral infarction. 
        Study by Ligeesh A et al showed higher plasma fibrinogen levels in 
ischemic and hemorrhagic stroke, comparatively higher levels in ischemic 
stroke. 
        Study by Kofoed S C et al showed elevated fibrinogen predicts future 
ischemic strokes particularly in men. 
        Study by Mario Di Napoli et al showed that higher levels have a greater 
risk if cardiovascular events in post stroke patients. 
        Study by Ziakas G N et al
 
showed significant relation between high 
cholesterol level, high fibrinogen level and ischemic stroke. 
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BARTHEL INDEX: 
The functional Outcome is measured using the Barthel index score. The 
index is used to record what a stroke patient does. First came in to limelight in 
1965 with a score of Zero to Twenty. Despite the fact that the initial version was 
still in use, Granger et al modified the score during early seventies, when he 
included zero to ten points for each variable. Again changes were done in 1989.  
This index had shown a worthy inter-rator reliability (0.95) & a high 
correlation i.e 0.74 up to 0.8, compared with other physical disability 
measurements. The reason for designing the modified Barthel index was that the 
first scale brought out was not sensitive to any change and it also had only 
arbitrary scores.  
Otherwise known as the Barthel ADL index it is an ordinal scale helping 
us to measure performances in ADL - activities in daily living.  Every 
performance item is given a rating using this scale with a score for every level 
exhibited by the patient. There are 10 different factors depicting ADL & 
mobility. Larger number will have an association with a higher probability of 
the patient being able to live independently at home after getting discharged 
from hospital  
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There are 10 items indicating a person's daily functions.  
FEEDING  BLADDER 
BATHING TOILET USE 
GROOMING TRANSFERS (bed/chair) 
DRESSING  MOBILITY (levels) 
BOWELS STAIR 
USAGE :  helps in determining a basal functional level of the patient and useful 
in monitoring any improvement in ADLs over time. Scoring is done  on the 
basis of whether they receive help for doing the task.varies between 0, 5,10,15 
Summation of scores of each of the items is done to get a final score. Greater 
the total score means more "independent" the patient is. A patient is 
independent when he does not need any assistance for any portion of the task. 
When he/she is able to do 50% of task independently “middle" score is given. In 
this manner a total score is calculated.  
Functional status was measured with Barthel Index of ADL. Accordingly, 
they were divided into 3 groups.   
    Score        Disability 
 < 41 Severely  
41-60 Moderately 
 >60 Mildly 
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AIMS AND OBJECTIVES:   
 
 
1. TO STUDY THE BIOCHEMICAL PARAMETERS URIC ACID 
CRP ESR FIBRINOGEN IN ISCHEMIC STROKE PATIENTS AT 
GOVERNMENT STANLEY HOSPITAL 
 
2. TO ASSESS FUNCTIONAL OUTCOME IN THESE PATIENTS 
USING BARTHEL INDEX AT ADMISSION AND AT 
DISCHARGE 
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MATERIALS AND METHODS 
PLACE OF STUDY: 
 
 DEPARTMENT OF GENERAL MEDICINE,  MEDICAL OPD, 
MEDICAL WARDS AND IMCU AT STANLEY MEDICAL COLLEGE 
AND HOSPITAL, CHENNAI. 
 
SAMPLE SIZE :   
75 
DURATION:   
JAN 2014 TO SEP 2014. 
 
STUDY DESIGN: 
 PROSPECTIVE OBSERVATIONAL STUDY 
ETHICAL COMMITTEE APPROVAL:  
THE ETHICAL COMMITTEE APPROVAL WAS OBTAINED FOR THIS 
STUDY 
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INCLUSION CRITERIA 
 
1. Any Patient coming with symptoms suggestive of Acute Stroke to 
medical outpatient department, wards and Intensive care unit.  
2. Proven by Imaging as Ischemic Stroke. 
3. Patients age more than 18 years 
 
EXCLUSION CRITERIA: 
 
1. Hemorrhagic stroke patients 
2. Patients with any source of Sepsis / Infectious Disease in prior 4 
weeks. 
3. Patients presenting after 72 hours of onset 
4. Patients having evidence of renal disease, active hepatic disease, 
history of prior MI/Ischemic Heart disease or surgery within preceding 
3 months. 
5. Patient with any form of Arthritis   
6. Recent Trauma/ burns. 
7. Patients with prior history of stroke or TIA‟s. 
8. Patients on any lipid lowering agents including fibrates. 
9. Patients with venous stroke and Stroke due to Tumours. 
 
73 
 
CONSENT 
The study group thus identified by the above criteria (inclusion and exclusion 
criteria) was first instructed about the nature of the study. Willing participants 
were taken up for this study after getting a written / informed consent from 
these patients or their relatives in the local vernacular language. 
 
 
 
 
 
 
 
 
STUDY SUBJECTS: 
 
All   the  patients  who  fulfilled  the  inclusion  criteria  above  18 years of  age  
and  both  genders  were  included  in  this  study. The  included  patients were 
subjected to detailed history taking, complete physical examination  and  the  
relevant  laboratory  investigations  as per a proforma, exclusively  designed  for  
the  study. 
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RESULTS & DISCUSSION 
The study includes total number of 75 patients. Data were collected and final 
analysis was made. 
Study Groups 
Treatment 
Groups 
Name of 
Group 
Study 
Number 
of 
Subjects 
Group A Mild 
To assess functional 
outcome in these 
patients using 
Barthel index in 
ischemic stroke 
patients 
75 
Group B Moderate 
Group C Severe 
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Statistics  
 
Descriptive statistics was done for all data and suitable statistical tests of 
comparison were done. Continuous variables were analysed with the Unpaired t 
test/Anova and categorical variables were analysed with the Chi-Square Test 
and Fisher Exact Test. Statistical significance was taken as P < 0.05. The data 
was analysed using EpiInfo software (7.1.0.6 version; Center for disease 
control, USA) and Microsoft Excel 2010. 
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Sample Size Calculation 
Sample size was determined on the basis of a pilot study in which the 
prevalence of  serum fibrinogen levels was measured at 25%.  We calculated a 
minimum sample size of 72 patients was required in each group, assuming a 
type 1 error (two-tailed) of 0.05 and a margin of error of 10%. Therefore, the 
final sample selected was n= 75.. 
 
 
 
n= t² x p(1-p) 
  m² 
Description: 
n = required sample size 
t = confidence level at 95% (standard value of 1.96) 
p = estimated prevalence of malnutrition in the project area 
m = margin of error at 10% (standard value of 0.05) 
n= (1.96)² x 0.25(1-0.75) 
             (0.01)² 
 
n= 3.8146 x 0.1875 
  
           0.0001 
 
= 138 
 
= 72 per group 
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Age  
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Age 
Groups 
All % Mild % Moderate % Severe % 
26 to 35 1 1.33 1 3.70 0 0.00 0 0.00 
36 to 45 10 13.33 3 11.11 3 17.65 4 12.90 
46 to 55 28 37.33 16 59.26 5 29.41 7 22.58 
56 to 65 17 22.67 3 11.11 4 23.53 10 32.26 
66 to 75 12 16.00 3 11.11 4 23.53 5 16.13 
75 to 85 7 9.33 1 3.70 1 5.88 5 16.13 
Total 75 100 27 100 17 100 31 100 
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Anova: Single Factor 
    
       
SUMMARY 
     
Groups Count Sum Average Variance 
  
Mild  27 1435 53.14815 100.1311 
  
Moderate  17 982 57.76471 169.9412 
  
Severe 31 1905 61.45161 139.1892 
  
       
       
ANOVA 
      Source of 
Variation SS Df MS F P-value F crit 
Between 
Groups 995.403 2 497.7015 3.122791 0.27656 3.773907 
Within 
Groups 9498.144 72 131.9187 
   
       
Total 10493.55 74         
 
 
By conventional criteria the association between the study groups 
and age is considered to be not statistically significant since p > 
0.05. 
81 
 
 
Gender 
 
 
 
 
41
34
0
5
10
15
20
25
30
35
40
45
Male Female
N
u
m
b
e
r 
o
f 
Su
b
je
ct
s
Gender Distribution
82 
 
 
 
 
 
41
18
7
16
34
9
10
15
0 10 20 30 40 50
All
Mild 
Moderate 
Severe
Number of Subjects
B
ar
th
e
l I
n
d
ex
Gender Distribution as per Barthel Index
Female
Male
83 
 
Gender All % Mild % Moderate % Severe % 
Male 41 54.67 18 66.67 7 41.18 16 51.61 
Female 34 45.33 9 33.33 10 58.82 15 48.39 
Total 75 100 27 100 17 100 31 100 
Chi-square 2.93  
Degrees of 
freedom 
2 
P value 
Chi squared 
test without 
yates correction 
0.231 
 
 
By conventional criteria the association between the study groups and gender is 
considered to be not statistically significant since p > 0.05. 
Since age and gender is not statistically significant, it means that there is no 
difference between the groups. In other words the groups contain subjects with 
the same basic demographic characteristics. 
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Duration of Stay in Hospital  
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Duration 
of Stay 
in days 
All % Mild % Moderate % Severe % 
≤ 6 15 20.00 10 37.04 2 11.76 3 9.68 
7 to 8 28 37.33 13 48.15 6 35.29 9 29.03 
9 to 10 17 22.67 2 7.41 7 41.18 8 25.81 
11 to 12 10 13.33 2 7.41 2 11.76 6 19.35 
13 to 14 5 6.67 0 0.00 0 0.00 5 16.13 
Total 75 100 27 100 17 100 31 100 
 
 
 
Anova 
      
       SUMMARY 
     Groups Count Sum Average Variance 
  Mild  27 197 7.296296 2.678063 
  Moderate  17 148 8.705882 3.345588 
  Severe 31 298 9.612903 6.445161 
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ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 77.83279 2 38.91639 8.85263 0.000365 3.123907 
Within 
Groups 316.5139 72 4.396026 
   
       Total 394.3467 74     
 
 
By conventional criteria the association between the study groups and duration 
of stay in hospital is considered to be statistically significant since p < 0.05. 
 
 
Statistical Significance 
This indicates that there is a true difference among the study groups and the 
difference is significant. In simple terms, by assessing the functional outcome 
using Barthel index in ischemic stroke patients,in mild patients category the 
average duration of stay in hospital was reduced significantly to 7.30 days in 
comparison to 8.71 days in moderate patient category and 9.61 days in severe 
patient category with a p-value of 0.000365 according to ANOVA test 
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Clinical Significance 
 
The average duration of stay in hospital by using Barthel index was 
meaningfully less(19.31%) inmild patients category compared to moderate 
patient category and also meaningfully less in moderate patient 
category(10.41%) compared to severe patient category. This difference is true 
and significant and has not occurred by chance. 
Conclusion  
We conclude that there is real advantage if the patient is classified under mild 
category using Barthel index, which in turn decreases the duration of stay in 
hospital. 
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Complications  
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Complications Mild Moderate Severe 
Hemiparesis/plegia 25 16 31 
Aphasia/Dysphasia 9 10 17 
CN involvement 23 16 25 
Altered Sensorium 0 1 18 
Headache 4 2 14 
Vomiting 1 3 4 
Seizures 1 0 3 
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Risk Factors 
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H/o Risk Factors Mild Moderate Severe 
Diabetes Mellitus 11 12 27 
Hypertension 7 12 25 
Smoking 6 2 9 
Alcoholism 6 2 11 
 
H/o Risk 
Factors 
Diabetes 
Mellitus 
Hypertension Smoking Alcoholism 
+ - + - + - + - 
Mild 27 11 16 7 20 6 21 6 21 
Moderate 17 12 5 12 5 2 15 2 15 
Severe 31 27 4 25 6 9 22 11 20 
Total 75 50 25 44 31 17 58 19 56 
Chi-square 14.1  19.1  1.87  3.48  
Degrees of 
freedom 
2 2 2 2 
P value 
Chi squared 
test without 
yates 
correction 
0.003 0.000 0.392 0.175 
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By conventional criteria the association between the study groups and risk 
factors like diabetes mellitus and hypertension is considered to be statistically 
significant since p < 0.05. 
Statistical Significance 
This indicates that there is a true difference among the study groups and the 
difference is significant.  
In simple terms, by assessing the functional outcome using Barthel index in 
ischemic stroke patients,in mild patients category the incidence of diabetes 
mellitus increases significantly from 11 in mild patient category to 12 and 27 in 
moderate and severe patient category with a p-value of 0.003 according to Chi-
Squared test. 
In simple terms, by assessing the functional outcome using Barthel index in 
ischemic stroke patients,in mild patients category the incidence of hypertension 
increases significantly from 7 in mild patient category to 12 and 25 in moderate 
and severe patient category with a p-value of 0.000 according to Chi-Squared 
test. 
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Clinical Significance 
 
The incidence of diabetes mellitus in patients classified using Barthel index was 
meaningfully less(22%) in mild patients category compared to moderate patient 
category(24%) and  severe patient category(54%). This difference is true and 
significant and has not occurred by chance. 
The incidence of hypertension & diabetes mellitus in patients classified using 
Barthel index was meaningfully less(15.91%) in mild patients category 
compared to moderate patient category(27.27%) and  severe patient 
category(56.82%). This difference is true and significant and has not occurred 
by chance. 
 
Conclusion  
We conclude that there is real advantage if the patient is classified under mild 
category using Barthel index, which in turn decreases the risk of having 
diabetes mellitus and hypertension. This also proves there is an increasing trend 
of diabetes mellitus and hypertension with stroke severity. 
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CRP 
Levels 
All % Mild % Moderate % Severe % 
≤ 6 18 24.00 11 40.74 3 17.65 4 12.90 
> 6 57 76.00 16 59.26 14 82.35 27 87.10 
Total 75 100 27 100 17 100 31 100 
 
 
Anova 
     
       SUMMARY 
      Groups Count Sum Average Variance 
  Mild  27 232.7 8.618518519 24.22926 
  Moderate  17 216.9 12.75882353 47.39632 
  Severe 31 560.1 18.06774194 92.78359 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 1299.405808 2 649.7029038 11.21303 0.000 3.123907 
Within 
Groups 4171.809659 72 57.94180082 
   
       Total 5471.215467 74     
 
By conventional criteria the association between the study groups and CRP 
levels is considered to be statistically significant since p < 0.05. 
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Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant. In simple terms, by assessing the functional outcome 
using Barthel index in ischemic stroke patients,in mild patients category the 
CRP levels was reduced significantly to 8.61 mg/dlin comparison to 12.75 
mg/dl in moderate patient category and 18.05 mg/dl in severe patient category 
with a p-value of 0.000 according to ANOVA test 
Clinical Significance 
 
The average CRP levels >6mg/dl in patients classified using Barthel index was 
meaningfully less (59.26%) in mild patients category compared to moderate 
patient category(82.35%) compared to severe patient category(87.10%). This 
difference is true and significant and has not occurred by chance. 
Conclusion  
We conclude that there is real advantage if the patient is classified under mild 
category using Barthel index, which in turn is associated with decreased CRP 
levels. This also proves there is an increasing trend of raised CRP levels with 
stroke severity. 
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ESR 
(mm-
hr) 
All % Mild % Moderate % Severe % 
≤ 10 33 44.00 19 70.37 5 29.41 9 29.03 
11 to 
20 
19 25.33 8 29.63 4 23.53 7 22.58 
21 to 
30 
19 25.33 0 0.00 6 35.29 13 41.94 
31 to 
40 
4 5.33 0 0.00 2 11.76 2 6.45 
Total 75 100 27 100 17 100 31 100 
 
Anova 
    
       SUMMARY 
     Groups Count Sum Average Variance 
  Mild  27 259 9.592593 7.789174 
  Moderate  17 318 18.70588 87.84559 
  Severe 31 609 19.64516 91.76989 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 1642.242 2 821.121 13.55624 0.000 3.123907 
Within Groups 4361.145 72 60.57145 
   
       Total 6003.387 74     
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By conventional criteria the association between the study groups and ESR 
levels is considered to be statistically significant since p < 0.05. 
Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant. In simple terms, by assessing the functional outcome 
using Barthel index in ischemic stroke patients,in mild patients category the 
ESR levels was reduced significantly to 9.59 mm -hr in comparison18.71mm - 
hr in moderate patient category and 19.65 mm -hr in severe patient category 
with a p-value of 0.000 according to ANOVA test 
Clinical Significance 
 
The average ESR levels in patients classified using Barthel index was 
meaningfully less (95%) in mild patients category compared to moderate patient 
category and also meaningfully less in moderate patient category(5.00%) 
compared to severe patient category. This difference is true and significant and 
has not occurred by chance. 
Conclusion  
We conclude that there is real advantage if the patient is classified under mild 
category using Barthel index, which in turn is associated with decreased ESR 
levels. This also proves there is an increasing trend of raised ESR levels with 
stroke severity. 
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Uric 
Acid  
(mg/dl) 
All % Mild % Moderate % Severe % 
≤ 7 27 36.00 19 70.37 6 35.29 2 6.45 
> 7 48 64.00 8 29.63 11 64.71 29 93.55 
Total 75 100 27 100 17 100 31 100 
 
 
Anova 
    
       SUMMARY 
     Groups Count Sum Average Variance 
  Mild  27 182 6.740741 8.968661 
  Moderate  17 153 9 7.5 
  Severe 31 344 11.09677 5.290323 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 273.8918 2 136.9459 19.26197 0.000 3.123907 
Within Groups 511.8949 72 7.109651 
   
       Total 785.7867 74     
 
By conventional criteria the association between the study groups and uric acid 
levels is considered to be statistically significant since p < 0.05. 
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Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant. In simple terms, by assessing the functional outcome 
using Barthel index in ischemic stroke patients,in mild patients category the uric 
acid levels was reduced significantly to 6.74 mg/dlin comparison9.00 mg/dlin 
moderate patient category and 11.10md/dl in severe patient category with a p-
value of 0.000 according to ANOVA test 
 
Clinical Significance 
 
The average uric acid levels in patients classified using Barthel index was 
meaningfully less (33.51%) in mild patients category compared to moderate 
patient category and also meaningfully less in moderate patient  
category(23.29%) compared to severe patient category. This difference is true 
and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is real advantage if the patient is classified under mild 
category using Barthel index, which in turn is associated with decreased uric 
acid levels. This also proves there is an increasing trend of raised uric acidlevels 
with stroke severity. 
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Fibrinogen 
(mg/dl) 
All % Mild % Moderate % Severe % 
≤ 400 44 58.67 23 85.19 9 52.94 12 38.71 
> 400 31 41.33 4 14.81 8 47.06 19 61.29 
Total 75 100 27 100 17 100 31 100 
 
 
Anova 
    
       SUMMARY 
     Groups Count Sum Average Variance 
  Mild  27 8794 325.7037 7284.14 
  Moderate  17 7043 414.2941 11233.22 
  Severe 31 14307 461.5161 19143.26 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 269546.6 2 134773.3 10.28567 0.000118 3.123907 
Within Groups 943416.9 72 13103.01 
   
       Total 1212964 74     
 
 
By conventional criteria the association between the study groups and serum 
fibrinogen levels is considered to be statistically significant since p < 0.05. 
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Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant. In simple terms, by assessing the functional outcome 
using Barthel index in ischemic stroke patients,in mild patients category the 
fibrinogen levels was reduced significantly to 325.70 mg/dl in 
comparison414.29 mg/dl in moderate patient category and 461.52 md/dl in 
severe patient category with a p-value of 0.000118  according to ANOVA test 
 
Clinical Significance 
 
The average fibrinogen levels in patients classified using Barthel index was 
meaningfully less (27.20%) in mild patients category compared to moderate 
patient category and also meaningfully less in moderate patient category 
(11.40%) compared to severe patient category. This difference is true and 
significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is real advantage if the patient is classified under mild 
category using Barthel index, which in turn is associated with decreased serum 
fibrinogen levels. This also proves there is an increasing trend of raised 
fibrinogen levels with stroke severity. 
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Site of 
Infarct 
All % Mild % Moderate % Severe % 
Carotid 
Artery 
71 94.67 24 88.89 17 100.00 30 96.77 
Vertebral 
Artery 
4 5.33 3 11.11 0 0.00 1 3.23 
Total 75 100 27 100 17 100 31 100 
Chi-square 3.70  
Degrees of freedom 2 
P value 
Chi squared test without 
yates correction 
0.157 
 
By conventional criteria the association between the study groups and site of 
infarct is considered to be not statistically significant since p > 0.05. 
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Barthel Score Admission Discharge 
N 75 67 
Mean 52.26667 56 
SD 28.96052 32.93113 
 
 
Barthel Score Admission % Discharge % 
Death 0 0 9 12.00 
Mild 27 36 34 45.33 
Moderate 17 22.66 15 20.00 
Severe 31 41.33 17 22.67 
Total 75 100 75 100 
P  Value 
Paired t test 
0.0000 
 
In our Study 66 patients got discharged and 9 patients expired. Mortality Rate 
12 %. By conventional criteria the association between the study groups and 
Barthel scores (Admission and Discharge) is considered to be statistically 
significant since p < 0.05. 
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Statistical Significance 
 
This indicates that there is a true difference among the study groups and the 
difference is significant. In simple terms, by assessing the functional outcome 
using Barthel index in ischemic stroke patients at admission and discharge, the 
average Barthel score in patients  at the time of admission was 52.27 in 
comparison to significantly increased Barthel score at discharge(56)  with a p-
value of 0.0000  according to paired t- test 
 
Clinical Significance 
 
The average Barthel scores  was meaningfully less (36%) in mild patients 
category compared to  compared to severe patient category(41.33) at admission.  
The average Barthel scores was meaningfully more (45.33%) in mild patients 
category compared to compared to severe patient category(22.67) at discharge. 
This difference is true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is real advantage if the patient is classified using Barthel 
index for diagnosis and prognosis, which in turn is associated with stroke 
severity. 
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CITATIONS: 
1) VK Singh et al studied the prognostic significance of CRP in ischemic stroke 
on 48 patients within 24 hours of ischemic stroke & at discharge and an 
association was examined. It showed that CRP is a better prognostic indicator of 
ischemic stroke at the time of discharge & has a greater utility in risk 
identification (P<0.05). Hence raised CRP values predict future outcomes in 
term of mortality and morbidity. 
2) Medhini et al studied on patient with ischemic stroke. Method used was Chi-
Sqaure and Fisher exact test. Study population was 100 patients. Conclusion 
was that patients with CRP < 6mg/dl suffered mild disease and had a good 
prognosis. Their Barthel scores improved with follow up. P value was 
significant. The association of CRP values at admission and its correlation with 
Barthel scores to assess the functional outcome of patient following ischemic 
stroke, suggest CRP as a good prognostic tool .Modified Barthel index is a good 
tool to assess the functional outcome of patients following ischemic stroke, in 
co-relation with CRP levels. Elevated CRP is highly sensitive, non specific and 
an independent risk factor for prediction of ischemic stroke. 
3) Muir et al. studied 228 ischemic stroke admissions. Median follow up was 
959 days. Geometric mean C - reactive protein concentration was >10.1 mg/L. 
It was found that survival in those with C-Reactive Protein> 10 mg/L was 
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significantly worse than in those with C-Reactive Protein < 10 mg/L (p 0.0009, 
log rank test).They concluded that C-Reactive Protein concentration is an 
independent predictor of survival after ischemic stroke. The single independent 
predictor of survival in this study was measurement of CRP within 72 hours of 
onset of symptoms. 
4) Jaroslaw Zaremba et al studied the association between ESR and Ischemic 
stroke. It was observed that there was a positive correlation between ESR values 
and the extent of local brain damage. 
5) Chamarro et al studied about early predictors of functional outcome of stroke 
using ESR, Study population : 208 ischemic stroke patients.  Methodology was 
Stepwise logistic regression analysis. Conclusion was that ESR was an 
independent predictor of short term stroke outcome. 
6) Titto et al studied Admission C – reactive protein after acute ischemic stroke 
and its association with stroke severity and mortality. Study population - 498 
patients. Patients were followed up and it was found out that admission CRP is 
associated with stroke severity and long term mortality when measured at least 
24 hours after onset. Hence CRP is an independent predictor of long term 
mortality after ischemic stroke 
7) Gregory et al studied relationship between fibrinogen levels and functional 
outcome from acute ischemic stroke. Method of study was Multiple Logistic 
regression analysis. Placebo data from the Stroke treatment with Ancrod Trial 
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(STAT) and European stroke treatment with Ancrod trial (ESAT) were 
analysed. In both univariate & multivariate analysis the proportion of patients 
with good functional outcome decreased with increasing quartiles of initial 
fibrinogen levels in both groups. Patient with initial fibrinogen levels < 450 
mg/dl had a better outcome. 
8) Arnon et al studied the inflammatory response in the first 48 hours of acute 
ischemic Stroke .Study duration 2005-2007. They concluded that significant 
increase in inflammatory substance in the first few days have an important role 
in ischemic brain injury and can affect the short as well as long term clinical 
outcome. 
9) William whitely et al from UK conducted a study to determine whether 
markers of inflammation (White cell count, CRP and fibrinogen are associated 
with a poor outcome after stroke. Study type Prospective study. Duration 2002-
2005.Population size – 844 .Confidence intervals were significant for these 
variables. Hence it concluded that raised levels of markers after stroke are 
associated with poor outcomes. 
10) Angel Chamorre et all study had a population of 881 patients with Acute 
ischemic stroke and found the association between functional outcome of stroke 
and uric acid measured at hospital admission. Method of study: logistic 
regression. In patients with acute ischemic stroke, there is a 12% increase in the 
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Odds of good clinical outcome for each milligram per decilitre increase of 
serum uric  acid. This finding reinforces the relevance of oxidative damage in 
ischemic stroke. 
11) H.J Milionis et al from UK studied in 163 patients for Serum uric acid 
levels and risk for acute ischemic non-embolic stroke in elderly subjects. It was 
a case–control study done in Greece. The association between SUA and stroke 
was determined by multivariate logistic regression modelling after adjusting for 
potential confounding factor. Elevated SUA is associated with an increased risk 
for acute ischemic/non-embolic stroke in a strictly defined population of elderly 
individuals independently of concurrent metabolic derangements.(P<0.05). 
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CONCLUSION: 
CRP apart from being an inflammatory marker has also been found to be 
a   highly sensitive, non specific and an independent risk factor for prediction of  
Ischemic stroke. Similarly ESR, fibrinogen, Uric acid have also been found to  
be useful as early indicator of prognosis in Stroke patients. 
 
         The present study is done without any haste involving the above four 
 parameters to predict the outcome among stroke patients. This study correlates 
with the previous studies done by eminent people as quoted by my citations 
  
        Inclusion of these tests in patients with acute stroke provides clinicians  
with a low cost and useful way to predict functional outcome after ischemic  
stroke, as measured by Barthel index which has been proved to have a strong  
correlation with inflammatory markers. 
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PROFORMA 
PRELIMINARY DATA OF THE PATIENT 
Name:   Age:    Sex:      IP NO: 
Address:          PH No: 
DOA:     DOD: 
Occupation:    Income:    Religion: 
     CONSENT  
I --------------------------------------- , unreservedly and in my full sense give my consent to take part in 
this study, the risks and benefits of which have been explained to me in my vernacular language 
CHIEF complaints: 
1) Weakness   : UL    
      LL  Present/absent     Present/absent 
     Face 
Since----- 
2) Deviation of mouth: Present/absent: to left/right Since------ 
3) Altered level of consciousness Present/absent Since------ 
PRESENTING COMPLAINTS: 
According to the patients /attenders words Right   Left 
Weakness:   UL    
    LL  Present/absent     Present/absent 
    Face 
Onset: Sudden /gradual /progression- over min /hours/days  
   During activity /at rest/during sleep 
 
Prodromal Symptoms: 
Headache within 2hrs of onset of weakness/giddiness/vertigo/vomiting: Present/absent 
 
H/o convulsions: Present/absent: If present: focal /generalised 
 
 H/o of loss of consciousness: Present/absent 
 Duration of altered State: 
 Onset:   Sudden /gradual 
   Deteriorating/Recovering 
 
Other symptoms: 
Bladder Bowel disturbance: Present/absent 
Involuntary movements: Present/absent 
Inability to speak/ altered speech: Present/absent 
H/o of cranial nerve involvement: H/o of loss of vision/ diplopia /change in voice/nasal 
regurgitation: Present/absent 
H/o of swaying present/absent 
H/o sensory disturbances: Present/absent 
H/o trauma (head): Present/absent 
H/o Chest pain /palpitation/dyspnoea/PND/orthopnoea 
H/o of joint pain /fever 
 
PAST MEDICAL HISTORY 
 
Diabetes Mellitus /  Hypertension / Intermittent Claudication/ TIA / VBI / Stroke/ Heart 
disease- IHD, RHD/ Trauma to head and spine/ Bleeding Diathesis/ Syphilis/ TB/ Migraine 
/Seizures/Gout  : - YES/NO 
 
Surgical history if any: 
 
Drug Intake: OCP/Anticoagulants/Cocaine/amphetamine/others 
 
FAMILY HISTORY: Hx of similar complaints/ stroke/ hypertension/ Sudden Death/ DM/ 
IHD/ Hyper-coagulable states. 
 
PERSONAL HISTORY 
Diet:Veg /Non Veg ;   
Smoking – Average no of Beedies /cigarettes smoked per day /no of years. Smoking index 
Appetite: Good /poor   
Sleep: Sound /disturbed 
Alcohol intake: 
a) Yes/No  
b) If yes - No of years, Nature of drink (brand) 
c) Amount consumed per day (Avg) Alcohol index ml/day *Duration in years 
d) Stopped?? 
Bowel and Bladder: Regular/altered 
Illicit drugs : Yes /No 
Marital status: married /unmarried 
Menstrual history if any: Age of menarche / menopause; Regular /irregular cycles  
 
Treatment history: if any  
 
GENERAL PHYSICAL EXAMINATION 
Built & Nourishment: Height in cm; Weight in Kg; BMI kg/m2 
Pallor / Cyanosis /Clubbing / Oedema / Icterus / Lymphadenopathy / edema 
Carotid Bruit 
Evidence of any congenital abnormalities 
 
VITAL PARAMETERS 
Pulse: Rate /Rhythm/Volume/Character/All peripheral pulses/ RR –RF delay/ 
Condition of the vessel wall: Bruit Thrill. 
Peripheral pulses: 
BP:in mmHG :  
  Supine    Standing    Standing 
Right UL:        Left UL:       Right UL:     Left UL:     Right LL: 
RR: .../min 
JVP: 
Temperature: in degree Celsius 
 
Neurocutaneous markers: Yes/No 
 
Skull /Spine:  
 
Thyroid/Breast: 
 
SYSTEMIC EXAMINATION 
 
A.CENTRAL NERVOUS SYSTEM 
    Handedness: Right /Left 
 
HMF 
Consciousness: Alert /drowsy/stuporous/comatose 
If alert  
Orientation: Time/place/person: present /absent 
Memory: Intact/Lost  
Speech and language: Normal/aphasic/dysarthric 
 
B. Cranial nerves: 
1. Olfactory (sense of smell-preserved/altered/lost) 
2. Optic: Visual acuity- normal /reduced 
Field of vision – normal /reduced 
Colour vision – normal /altered 
Fundus : normal/abnormal 
3/4/6.Oculomotor, Trochlear, Abducent 
  Eye movement –individual &conjugate – full range /restricted 
Nystagmus: present /absent 
Squint: present /absent 
Ptosis: present /absent 
   
RIGHT  LEFT 
Pupils’ size:    
Light Reflex 
Accommodation Reflex 
5. Trigeminal (Sensation of face jaw and motor): 
 MOTOR 
 Sensory 
 Secretory 
 Reflexes: corneal /conjunctival/jaw jerks 
7. Facial (motor, taste anterior 2/3 of tongue, stapedial reflex, lacrimation) 
8. Vestibulocochlear nerve (Rinnes and Webers) 
9. Glossophayngeal and 10.Vagal (uvula position, palatal movement, gag reflex or 
pharyngeal reflex) 
11. Accessory (SCM and trapezius) 
12. Hypoglossal (tongue wasting fasciculations, deviation, power) 
Right    Left  
C.Motor System  
1. Bulk: wasting /atrophy measure  UL and LL 
2. Tone: normal/hypo/hyper 
3. Power MRC scale 0-5 
Neck 
 Flexors  
 Extensors  
     RIGHT    LEFT 
UL   
Shoulder  
 Flexion 
 Extension 
                 
 Abduction 
 Adduction 
Elbow  
Flexion 
Extension 
Wrist 
 Flexion 
 Extension 
Hand Grip  
Lower Limbs: 
Hip 
 Flexion 
 Extension 
 Abduction 
 Adduction 
Knee 
 Flexion 
 Extension 
Ankle  
 Dorsi-Flexion 
 Plantar Flexion 
 Inversion 
 Eversion 
Toe Grip 
 
4. Co-ordination: 
Upper Limbs: 
 Finger nose & Finger Finger Nose Test 
 Dysdiadokinesia 
 
Lower limbs 
 Heel knee test 
 Tandam walking 
 Rhombergs Test 
 
Other cerebellar Signs: 
Dysmetria 
Rebound phenomenon 
  Pendular knee jerk 
  Nystagmus  
  Scanning speech 
 
5. Involuntary movements: 
6. Gait: 
D. Sensory System:  
Touch      Affected or not affected  
Pain 
Temperature 
Position Sense 
Vibration sense 
Cortical sensation 
Graphaesthesia 
Stereognosis 
 
Tactile Localisation  
Sensory inattention 
 
E.Reflexes  
1. Superficial  
 A) Corneal 
 B) Conjunctival 
 C) Pharyngeal (gag) 
 D) Abdominal: Upper and lower 
 E) Cremastric 
 F) Plantar 
 
2. DTR: 
   BICEPS   TRICEPS    SUPINATOR   FINGERFLEXOR  KNEE  ANKLE 
Right  
Left 
 
Other: Jaw jerk /Hoffmans sign – R/L  
 
Clonus: Ankle and patellar 
 
3. Primitive Reflexes : present /absent. 
 Glabellar tap/ palmomental/ Snout/ Sucking/ Grasp reflexes 
4. Visceral reflexes – Bulbo-cavernous and anal reflex 
F. Meningeal Signs:  
 
RESPIRATORY SYSTEM: 
Respiratory Rate: Rhythm 
Any features suggestive of Aspiration Pneumonia: 
 
CVS: 
 
ABDOMEN:  
INVESTIGATIONS: 
Blood: 
Hb% 
TC, DC 
 
Bl Urea: 
S.Creatinine: 
 
RBS/  FBS / PPBS 
 
S Electrolytes : Na    K 
 
Urine Routine Examination: Albumin   Sugar   deposits 
 
CXR-PA View: 
 
ECG: 
 
Fasting Lipid Profile:  
TC:   
LDL:    
HDL:    
VLDL:    
TG:    
 
ESR:     
 
Serum CRP:   
 
Serum Uric Acid 
 
Plasma Fibrinogen 
 
2D – ECHO 
 
CT scan Brain: - Infarct Region-    Infarct size- 
 
PROVISIONAL / CLINICAL DIAGNOSIS: 
 
TREATMENT GIVEN:  
 
Date of Discharge / Death:     
 
 
 
 
STATUS AT DISCHARGE: ---------- 
 
 
 
THE BARTHEL INDEX 
 
Patient Name: ____________ Rater Name: _________________Date: ___________ 
Activity Score 
FEEDING________ 
0 = unable 
5 = needs help cutting, spreading butter, etc., or requires modified diet 
10 = independent  
BATHING________ 
0 = dependent 
5 = independent (or in shower)  
GROOMING________ 
0 = needs to help with personal care 
5 = independent face/hair/teeth/shaving (implements provided)  
DRESSING________ 
0 = dependent 
5 = needs help but can do about half unaided 
10 = independent (including buttons, zips, laces, etc.) 
BOWELS________ 
0 = incontinent (or needs to be given enemas) 
5 = occasional accident 
10 = continent  
BLADDER________ 
0 = incontinent, or catheterized and unable to manage alone 
5 = occasional accident 
10 = continent  
TOILET USE________ 
0 = dependent 
5 = needs some help, but can do something alone 
10 = independent (on and off, dressing, wiping)  
TRANSFERS (BED TO CHAIR AND BACK) ________ 
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit 
10 = minor help (verbal or physical) 
15 = independent  
MOBILITY (ON LEVEL SURFACES) ________ 
0 = immobile or < 50 yards 
5 = wheelchair independent, including corners, > 50 yards 
10 = walks with help of one person (verbal or physical) > 50 yards 
15 = independent (but may use any aid; for example, stick) > 50 yards 
STAIRS ________ 
0 = unable 
5 = needs help (verbal, physical, carrying aid) 
10 = independent  
 
 
 
 
TOTAL (0–100): ______ 
 
GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
A STUDY ON BIOCHEMICAL PARAMETERS ESR,CRP, URIC ACID AND FIBRINOGEN FOR PREDICTION 
OF FUNCTIONAL OUTCOME IN PATIENTS WITH ISCHEMIC STROKE AT GOVERNMENT STANLEY 
HOSPITAL, CHENNAI. 
 
Place of study:  govt. Stanley medical college, Chennai 
 
I ……………………………………………. have been informed about the details of the study in my own 
language. 
I have completely understood the details of the study. 
I am aware of the possible risks and benefits, while taking part in the study. 
I understand that I can withdraw from the study at any point of time and even then, I can receive the 
medical treatment as usual. 
I understand that I will not get any money for taking part in the study. 
I will not object if the results of this study are getting published in any medical journal, provided my 
personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I would extend my full 
cooperation for this study.   
  
 
 Volunteer:       Witness: 
Name and address        Name and address  
Signature/thumb impression:     Signature/thumb impression 
Date:        Date: 
  
 
 
Investigator  
Signature and date 
 
 
இ஭த்த நாரங்கரின் அடைப்பினால் பக்கவாதம் ஏற்பட்டு அ஭சாங்க 
ஸ்ைான்யி ஫ருத்துவ஫டனக்கு வரும் நநா஬ாரிகரின் இ஭த்த சிஆர்பி 
இஎஸ்ஆர் யூரிக் ஆஸிட் டபபிரிநனாஜன் என்னும் பரிநசாதடை 
மூயம் அவர்கரின் சச஬ல்பாட்டு விடரவிடன கண்ைமி஬ ஒரு ஆய்வு 
ஆய்யா஭ர்:மரு.விநனாத் கு஫ார், 
முது஥ில஬஧ட்டமநற்஧டிப்புநாணயர், 
ப ொதுமருத்துவ ஧ட்ட஧டிப்பு. 
யமிகாட்டி : பேராசிரியர் மரு. வசு஫தி  ஜ,ீ 
ப ொதுமருத்துவம஧பாசிரினர், 
அபசுஸ்டான்஬ிநருத்துயநல஦. 
சுயஒப்புதல்ேடிவம் 
ப஧னர்:                                     யனது:                    உள்஭ிருப்புஎண்: 
இந்த நருத்துய ஆய்யின் யியபங்கள் எ஦க்கு யி஭க்கப்஧ட்டது . என்னுலடன 
சந்மதகங்கல஭க்மகட்கவும் ,அதற்கா஦ தகுந்தயி஭க்கங்கல஭ப்ப஧஫வும் யாய்ப்஧஭ிக்கப்஧ட்டது . 
஥ான் இவ்யாய்யில் தன்஦ிச்லசனாகத்தான் ஧ங்மகற்கிம஫ன் . எந்த காபணத்தி஦ாலும் ,எந்தகட்டத்திலும் , 
எந்த சட்டசிக்கலும் இன்஫ி இந்த ஆய்யி஬ிருந்து யி஬கிக்பகாள்஭஬ாம் என்றும் அ஫ிந்துபகாண்மடன் . 
஥ான் ஆய்யி஬ிருந்து யி஬கிக்பகாண்டாலும் ஆய்யா஭ர் என்னுலடன நருத்துய 
அ஫ிக்லககல஭ப்஧ார்ப்஧தற்மகா அல்஬து உ஧மனாகிக்கமயா என் அனுநதி மதலயனில்ல஬ எ஦வும் 
அ஫ிந்துபகாண்மடன் .என்ல஦ப்஧ற்஫ின தகயல்கள் இபகசினநாகப்஧ாதுகாக்கப்஧டும் என்஧லதம௃ம் 
அ஫ிமயன். 
இந்த ஆய்யின் மூ஬ம் கிலடக்கும் தகயல்கல஭ம௃ம் ஧ரிமசாதல஦ முடிவுகல஭ம௃ம் .ஆய்யா஭ர் அயர் 
யிருப்஧த்திற்மகற்஧ எவ்யிதநாகப்஧னன்஧டுத்திக்பகாள்஭வும் , அதல஦஧ிபசுரிக்கவும் முழுந஦துடன் 
சம்நதிக்கிம஫ன். 
இந்த ஆய்யில் ஧ங்கு பகாள்஭  ஒப்புக்பகாள்கிம஫ன் . எ஦க்குபகாடுக்கப்஧ட்ட அ஫ிவுலபக஭ின்஧டி 
஥டந்துபகாள்யதுடன், ஆய்யா஭ருக்கு உண்லநம௃டன் இருப்ம஧ன் என்றும் உறுதின஭ிக்கிம஫ன் .என் 
உடல்஥஬ம் ஧ாதிக்கப்஧ட்டாம஬ா அல்஬து யமக்கத்திற்கு நா஫ா஦ம஥ாய்க்கு஫ிபதன்஧ட்டாம஬ா உடம஦ 
அலத பதரியிப்ம஧ன் எ஦ உறுதிகூறுகிம஫ன் . 
இந்த ஆய்யில் எ஦க்கு எவ்யிதநா஦ ஧ரிமசாதல஦கல஭ம௃ம் , சிகிச்லசகல஭ம௃ம் மநற்பகாள்஭ ஥ான் 
முழுந஦துடன் சம்நதிக்கிம஫ன் . 
இப்஧டிக்கு 
ம஥ான஭ினின் லகபனாப்஧ம்       ஆய்யா஭ர்லக பனாப்஧ம்/ப஧னர்                                                                      
(நரு. விநனாத் கு஫ார்.) 
                          
(ப஧னர்:                 ) 
 
இ஭த்த நாரங்கரின் அடைப்பினால் பக்கவாதம் ஏற்பட்டு அ஭சாங்க 
ஸ்ைான்யி ஫ருத்துவ஫டனக்கு வரும் நநா஬ாரிகரின் இ஭த்த சிஆர்பி 
இஎஸ்ஆர் யூரிக் ஆஸிட் டபபிரிநனாஜன் என்னும் பரிநசாதடை 
மூயம் அவர்கரின் சச஬ல்பாட்டு விடரவிடன கண்ைமி஬ ஒரு ஆய்வு 
ஆய்யா஭ர்:மரு.விநனாத் கு஫ார், 
முது஥ில஬஧ட்டமநற்஧டிப்புநாணயர், 
ப ொதுமருத்துவ ஧ட்ட஧டிப்பு. 
யமிகாட்டி : பேராசிரியர் மரு. வசு஫தி  ஜ,ீ 
ப ொதுமருத்துவம஧பாசிரினர், 
அபசுஸ்டான்஬ிநருத்துயநல஦. 
 
ேங்பேற்ோளரின் தேவல் ேடிவம் 
஥ீங்கள் இந்த ஆய்யில் ஧ங்மகற்க அலமக்கப்஧டுகி஫ரீ்கள் . இந்த ஆய்யில் ஧ங்மகற்கும்முன் , இதன் 
ம஥ாக்கத்லதம௃ம், முல஫கல஭ம௃ம் ,இத஦ால் ஏற்஧டும் ஧ின்யில஭வுகல஭ம௃ம் ஥ீங்கள் அ஫ிந்து பகாள்஭ 
ஆய்யா஭ர் அ஭ிக்கும் தகயல் : 
உங்கள் ம஥ானின் யப஬ாறும் , உங்க஭ின் முழு உடல்஧ரிமசாதல஦ம௃ம் பத஭ியாகவும் யிரியாகவும் 
஧திவுபசய்னப்஧டும். 
இந்த ஆய்யின் முடிவுகள் நருத்துய காபணங்களுக்காகவும் , நருத்துய கல்யிக்காகவும் 
஧னன்஧டுத்தப்஧டும் . இந்த ஆய்வு ஧ற்஫ின சந்மதகங்களுக்கு உரின முல஫னில் யி஭க்கந஭ிக்கப்஧டும் . 
தங்கல஭ப்஧ற்஫ின தகயல்கள் இபகசினநாக ஧ாதுகாக்கப்஧டும் . 
இந்த ஆய்யில் இருந்து எப்ம஧ாது மயண்டுநா஦ாலும் தாங்கள் எவ்யித முன்஦஫ியிப்஧ின்஫ிம௃ம் , எவ்யித 
சட்டசிக்கலும் இன்஫ி யி஬கிக்பகாள்஭஬ாம் . 
இந்த ஆய்யில் ஧ங்மகற்குநாறு மகட்டுக்பகாள்கிம஫ன் . 
஥ன்஫ி, 
 
ஆய்யா஭ர் லகபனாப்஧ம்      ம஥ானா஭ினின் லகபனாப்஧ம்  
( நரு. விநனாத் கு஫ார்)                                 (ப஧னர்:                 ) 
 
 
 
 
SLN  Age  Sex  Duration 
stay 
Symptom DM HTN SMOKE Ethanol 
1 39 M 10 1,3 - + - - 
2 70 M 5  1,3 + - + - 
3 33 M 8  1,3,v - - - + 
4 65 M 7  1,2,3,h + + + + 
5 62 M 14 1,2,3,4h + + + + 
6 40 M 10 1,3 - + + - 
7 52 M 6  1,3 - - - - 
8 48 M 8  1,3,S - - + + 
9 51 M 6  1,h + - + - 
10 55 M 9  1,2,3, + + - - 
11 62 M 5  1,3 - - - - 
12 58 M 10 1,2,3,s + + + + 
13 56 F 6  2,h + - - + 
14 60 F 8  1,2,3, - - - - 
15 72 F 7  2 + - - - 
16 77 F 11 1,4,v + + - - 
17 70 F 9 1,3,h + + - - 
18 47 F 7 1,2,s + + - - 
19 49 F 8 1,3,v + + - - 
20 42 M 9 1,4,v + - + - 
21 52 M 7 1,2,h + + + - 
22 55 M 9 1,3,h + + + + 
23 80 F 10 1,3,v,h + - - - 
24 63 M 11 1,2,3,h + + - - 
25 75 F 12 1,4,h + + - - 
26 51 M 8 1,3,v + - + + 
27 45 M 7 1,2,3,h + + - - 
28 63 F 13 1,3,h + - - + 
29 55 F 6 1,4,h + + - - 
30 54 F 12 1,3,h + - - - 
31 74 F 10 1,2,3,v + - - - 
32 50 F 8  1,2,3, - - - - 
33 49 F 5  2 - - - - 
34 72 F 6  1,2,3 + + - - 
35 60 F 10 1,2,3,4,h,s + + - + 
36 47 F 11 1,2,3 + + - - 
37 48 M 7  1,3 - - + + 
38 44 M 14 1,2,3,h - + - - 
39 38 M 6 1,3, - - + - 
40 39 M 8 1,3, - - + + 
41 80 M 6 1,2,3 + + + + 
42 46 M 7 1,2,3, + - - - 
43 40 M 12 1,2,3,4,h,v - - + + 
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44 70 F 10 1,2,3,h + + - - 
45 56 M 7 1,3 + - + - 
46 54 M 6 1,2,3 + + + - 
47 58 F 10 1,3,4 + + - - 
48 76 F 11 1,3 + + - - 
49 65 F 12 1,3,4 + + - - 
50 61 M 8 1,3 + + + - 
51 80 F 7 1,3, + + - - 
52 68 M 8 1,3 + + - + 
53 50 M 6 1,3 - - + - 
54 55 M 9 1,2,3 - - + - 
55 48 M 11 1,2,3 - - - - 
56 56 M 12 1,2,3,4 - + - + 
57 66 M 7 1,3 + + + + 
58 54 M 6 1,3 - + + - 
59 65 F 7 1,3 + + - + 
60 77 F 7 1,3,h + + - - 
61 70 F 9 1,2,3,4 + + - - 
62 47 F 6 1,3 - - - - 
63 49 F 6 1,3 - + - - 
64 42 M 7 1,3 - - + - 
65 52 M 8 1,2,3 + + - - 
66 55 M 13 1,2,3,4,h + + - - 
67 80 F 14 1,2,3,4,h + + - - 
68 63 M 8 1,2,3 + + - + 
69 75 F 7 1,2,3 + + - - 
70 51 M 8 1,2,3 - + + - 
71 45 M 10 1,2,3 - + - - 
72 63 F 10 1,2,3,h,v + - - - 
73 55 F 9 1,3, + - - - 
74 54 F 8 1,3 - + - - 
75 74 F 8 1,2,3 + - - - 
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SLN  CRP ESR UA F CT BRAIN SITE OF INFARCT C/V BIA BID OUTCOME 
1 15.6 26 9 449 Right internal Capsule infarct C 60 70  
2 2.8 10 5 331 Left lacunar infarct C 85 90  
3 2 12 4 392 Left parietal infarct C 80 85  
4 25 28 10 300 Right Internal Capsule & corona infarct C 15 20  
5 8 13 8 556  Corona infarct and right IC infarct C 15 15 expired 
6 6 20 9 350 Left internal capsular infarct C 60 70  
7 7 12 6 280 Right capsuloganglionic infarct C 70 80  
8 24 8 10 526 Left Thalamic infarct C 85 90  
9 15 8 6 440 Left Thalamic infarct C 85 95  
10 30 30 12 580 Multiinfarct C 20 20  
11 6 10 5 280 Left lacunar infarct C 90 95  
12 26 28 12 650 Multiinfarct C 5 5 expired 
13 10 8 4 280 Left cerebellar infarct V 95 95  
14 15 10 7 560 Bilateral lacunar infarct C 85 90  
15 15 12 8 240 Left cerebellar infarct V 95 95  
16 11 16 10 300 left internal capsule infarct C 20 20  
17 13 4 13 209 left lacunar infarct C 35 30  
18 5.6 9 14 290 left parietal infarct C 40 30  
19 3.4 6 9 336 Right capsuloganglionic infarct C 60 70  
20 10 10 8 345 right thalamic infarct C 40 45  
21 4.1 9 6 321 right internal capsule infract C 75 80  
22 6 8 12 445 Left parietal infarct C 40 45  
23 8.4 5 10 430 right parietal infarct C 50 55  
24 3 13 12 420 corona radiata infract C 40 40  
25 12.4 17 11 320 left internal capsule infarct C 30 30  
26 15 12 8 330 left capsuloganglionic infarct C 20 20  
27 12.3 10 9 380 left lacunar infarct C 30 35  
28 11 9 8 290 right lacunar infarct C 25 30  
29 7.8 8 7 272 multi infarct C 10 10 expired 
30 8 12 8 286 right occipital infarct C 80 85  
31 7 13 6 350 Left internal capsular infarct C 55 60  
32 8 12 6 280 right thalamic infarct C 95 100  
33 16 28 12 290 Left corona radiata infarct C 50 60  
34 30 34 12 654 Bilateral lacunar infarct C 50 50  
35 26 28 10 610 Bilateral Capsuloganglionic  infarct C 15 15 expired 
36 24 30 9 590 Internal capsular infarct C 55 60  
37 12 15 18 370 left internal capsule infarct C 70 70  
38 13 10 8 400 Pontine infarct V 0 0 expired 
39 8 8 5 280 left lacunar infarct C 80 90  
40 10 10 4 250 right lacunar infarct C 80 90  
41 30 28 12 557 Left parietal infarct C 30 40  
42 11 8 12 386 right thalamic infarct C 95 100  
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SLN  CRP ESR UA F CT BRAIN SITE OF INFARCT C/V BIA BID OUTCOME 
43 25 26 14 670 multi infarct C 10 10 expired 
44 16 32 15 580 left internal capsule infarct C 55 60  
45 13 22 11 420 right parieto occipital infarct C 60 70  
46 9 13 8 350 Internal capsular infarct C 70 80  
47 15 22 6 420 Multiple lacunes C 60 65  
48 14 16 9 432 left capsuloganglionic infarct C 80 85  
49 28 30 14 670 Bilateral internal capsular infarct C 0 15  
50 14 18 12 546 corona radiata infract C 40 45  
51 16 30 14 550 Multi infarct  C 20 20  
52 18 24 12 448 left internal capsule infarct C 40 45  
53 5 8 6 220 Left lacunar infarct C 90 100  
54 6 8 7 280 Left lacunar infarct C 90 100  
55 5.5 10 5 276 Right Centrum semiovale C 60 70  
56 34 36 13 594 Left internal capsular infarct C 30 30  
57 10 10 8 360 Left cerebellar infarct V 85 90  
58 6 6 6 245 Left lacunar infarct C 90 95  
59 13 18 12 450 left external capsular infarct C 45 45  
60 15 16 14 521 Multi infarct  C 10 10  
61 30 28 11 550 Multi infarct  C 10 10 expired 
62 2.8 6 4 245 Left lacunar infarct C 80 90  
63 3 6 7 274 Left internal capsular infarct C 40 50  
64 4 4 5 323 corona radiata infract C 80 90  
65 9 10 7 348 Right MCA infarct C 60 70  
66 36 28 10 612 Bilateral infarct C 10 10 expired 
67 28 34 12 564 Bilateral infarct C 0 0 expired 
68 10 8 6 390 Right internal capsular infarct C 50 60  
69 17 22 8 364 left capsuloganglionic infarct C 55 60  
70 4 6 4 267 lacunar infarct left C 90 100  
71 8 12 7 346 Right MCA infarct C 50 60  
72 26 28 14 490 Left MCA/ACA infact C 40 40  
73 6 8 6 290 Left thalamic infarct C 85 95  
74 8 10 5 280 lacunar infarct right  C 90 100  
75 22 24 13 564 Left MCA/ACA infact C 30 30  
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KEY TO MASTER CHART 
 
SLN - SERIAL NUMBER  
 
SEX 
M - MALE 
F – FEMALE 
 
DURATION : NUMBER OF DAYS 
 
SYMTPOMS 
1- HEMIPARESIS/HEMIPLEGIA 
2.APHASIA /DYSPHASIA 
3.CRANIAL NERVE INVOLVEMENT 
4.ALTERED SENSORIUM 
 
H -HEADACHE 
V -VOMITTING  
S -SEIZURES  
 
DM - DIABETES MELLITUS  
HTN - HYPERTENSION 
 
CRP - C-REACTIVE PROTEIN mg/l 
ESR - ERYTHROCYTE SEDIMENTATION RATE mm first hr 
UA - URIC ACID mg/dL 
F -FIBRINOGEN mg/dl 
 
ARTERIAL TERRITORY 
C- CAROTID  
V- VERTEBRAL 
 
 
BIA : BARTHEL INDEX AT ADMISSION 
BID : BARTHEL INDEX AT DISCHARGE 
